[
    {
        "id": "dashboard-item-1759853783245-patient-context",
        "type": "component",
        "x": -1150,
        "y": 3600,
        "width": 1600,
        "height": "auto",
        "componentType": "PatientContext",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Patient Context",
            "component": "PatientContext",
            "props": {
                "patientData": {
                    "patient": {
                        "name": "Sarah Miller",
                        "date_of_birth": "1962-03-15",
                        "age": 63,
                        "sex": "Female",
                        "age_at_first_encounter": 53,
                        "identifiers": {
                            "mrn": "MC-001001"
                        }
                    },
                    "riskLevel": "high",
                    "primaryDiagnosis": "Rheumatoid arthritis",
                    "problem_list": [
                        {
                            "name": "Rheumatoid arthritis",
                            "status": "active"
                        },
                        {
                            "name": "Essential hypertension",
                            "status": "active"
                        },
                        {
                            "name": "Mild chronic kidney disease",
                            "status": "active"
                        }
                    ],
                    "medication_timeline": [
                        {
                            "name": "Methotrexate",
                            "dose": "20 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2018-09-05"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2015-08-10"
                        },
                        {
                            "name": "Lisinopril",
                            "dose": "10 mg",
                            "route": "PO",
                            "frequency": "daily",
                            "start": "2018-09-05"
                        },
                        {
                            "name": "Trimethoprim-Sulfamethoxazole",
                            "dose": "800/160 mg",
                            "route": "PO",
                            "frequency": "BID",
                            "start": "2025-06-15",
                            "end": "2025-06-25"
                        }
                    ],
                    "allergies": [
                        "Penicillin (rash)"
                    ]
                }
            }
        },
        "createdAt": "2025-10-14T16:16:23.245Z",
        "updatedAt": "2025-10-14T16:16:23.245Z"
    },
    {
        "id": "dashboard-item-1759906076097-medication-timeline",
        "type": "component",
        "x": 500,
        "y": 3600,
        "width": 1600,
        "height": "auto",
        "componentType": "MedicationTimeline",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Medication Timeline",
            "component": "MedicationTimeline",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2015-08-10",
                        "type": "Rheumatology Initial Consult",
                        "provider": "Dr. Elizabeth Hayes",
                        "diagnosis": "Seropositive Rheumatoid Arthritis (active)",
                        "medications": [
                            "Methotrexate 10mg weekly",
                            "Folic Acid 5mg weekly"
                        ],
                        "notes": "Started MTX therapy with folic acid supplementation"
                    },
                    {
                        "encounter_no": 2,
                        "date": "2016-02-20",
                        "type": "General Practice",
                        "provider": "GP",
                        "diagnosis": "Stable RA on MTX",
                        "medications": [
                            "Methotrexate 10mg weekly",
                            "Folic Acid 5mg weekly"
                        ],
                        "notes": "Good RA control on MTX 10 mg weekly; no MTX side effects"
                    },
                    {
                        "encounter_no": 3,
                        "date": "2018-09-05",
                        "type": "General Practice",
                        "provider": "GP",
                        "diagnosis": "New essential hypertension; RA stable; plan MTX dose increase",
                        "medications": [
                            "Methotrexate 20mg weekly",
                            "Folic Acid 5mg weekly",
                            "Lisinopril 10mg daily"
                        ],
                        "notes": "Elevated BP readings 145\u2013155/90\u201395; MTX increased to 20mg"
                    },
                    {
                        "encounter_no": 4,
                        "date": "2021-03-15",
                        "type": "General Practice",
                        "provider": "GP",
                        "diagnosis": "Stable RA; controlled HTN; mild CKD (stable)",
                        "medications": [
                            "Methotrexate 20mg weekly",
                            "Folic Acid 5mg weekly",
                            "Lisinopril 10mg daily"
                        ],
                        "notes": "Overall well; RA controlled on MTX 20 mg; BP controlled"
                    },
                    {
                        "encounter_no": 5,
                        "date": "2025-06-15",
                        "type": "General Practice",
                        "provider": "GP",
                        "diagnosis": "Acute bacterial sinusitis; RA/HTN/CKD stable",
                        "medications": [
                            "Trimethoprim-Sulfamethoxazole 800/160mg BID"
                        ],
                        "notes": "5 days nasal congestion, facial pain, headache, green discharge"
                    },
                    {
                        "encounter_no": 6,
                        "date": "2025-06-21",
                        "type": "Emergency Medicine",
                        "provider": "Dr. Sarah Chen",
                        "diagnosis": "Acute liver injury likely DILI and/or severe methotrexate toxicity",
                        "medications": [],
                        "notes": "Severe fatigue, jaundice, epigastric pain, confusion"
                    }
                ],
                "medicationTimeline": [
                    {
                        "name": "Methotrexate",
                        "startDate": "2015-08-10",
                        "endDate": "2018-09-05",
                        "dose": "10mg weekly",
                        "indication": "RA"
                    },
                    {
                        "name": "Methotrexate",
                        "startDate": "2018-09-05",
                        "dose": "20mg weekly",
                        "indication": "RA"
                    },
                    {
                        "name": "Folic Acid",
                        "startDate": "2015-08-10",
                        "dose": "5mg weekly",
                        "indication": "MTX supplementation"
                    },
                    {
                        "name": "Lisinopril",
                        "startDate": "2018-09-05",
                        "dose": "10mg daily",
                        "indication": "Hypertension"
                    },
                    {
                        "name": "Trimethoprim-Sulfamethoxazole",
                        "startDate": "2025-06-15",
                        "endDate": "2025-06-25",
                        "dose": "800/160mg BID",
                        "indication": "Acute bacterial sinusitis"
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:47:56.098Z",
        "updatedAt": "2025-10-14T16:47:56.098Z"
    },
    {
        "id": "dashboard-item-1759906219477-adverse-event-analytics",
        "type": "component",
        "x": -1150,
        "y": 4200,
        "width": 1600,
        "height": "auto",
        "componentType": "AdverseEventAnalytics",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Adverse Event Analytics",
            "component": "AdverseEventAnalytics",
            "props": {
                "patientData": {
                    "adverseEvents": [
                        {
                            "event": "Drug-Induced Liver Injury (DILI)",
                            "severity": "Severe",
                            "description": "Acute hepatocellular injury with jaundice and encephalopathy following TMP-SMX initiation in patient on chronic MTX"
                        },
                        {
                            "event": "Hepatic Encephalopathy",
                            "severity": "4",
                            "description": "Asterixis, disorientation to time/place, GCS 13 (E4 V3 M6)"
                        },
                        {
                            "event": "Acute Liver Failure",
                            "severity": "4",
                            "description": "ALT/AST >20\u00d7 ULN, INR elevated, bilirubin \u22653\u00d7 ULN with clinical jaundice"
                        },
                        {
                            "event": "Methotrexate Toxicity",
                            "severity": "Severe",
                            "description": "Synergistic hepatotoxicity with TMP-SMX; oral mucosal ulcerations present"
                        }
                    ],
                    "rucam_ctcae_analysis": {
                        "rucam": {
                            "title": "RUCAM Scoring (Hepatocellular pattern)",
                            "columns": [
                                "#",
                                "Parameter",
                                "Key findings from this case",
                                "Score",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "1",
                                    "Time to onset (from drug start to injury)",
                                    "TMP-SMX started Jun 15 \u2192 symptoms Jun 20 \u2192 presentation Jun 21 (\u22486 days)",
                                    "+2",
                                    "Compatible interval for idiosyncratic hepatocellular DILI (5\u201390 days)."
                                ],
                                [
                                    "2",
                                    "Course after stopping the drug",
                                    "TMP-SMX and MTX held on admission; recovery not yet documented but improvement expected",
                                    "+1",
                                    "Early improvement expected; data incomplete at time of scoring."
                                ],
                                [
                                    "3",
                                    "Risk factors",
                                    "Age 53 (+1); chronic alcohol consumption (+1)",
                                    "+2",
                                    "Age >55 and ongoing alcohol use increase risk."
                                ],
                                [
                                    "4",
                                    "Concomitant drugs",
                                    "Methotrexate (hepatotoxic; interacts with TMP-SMX)",
                                    "-1",
                                    "Confounding co-drug complicates attribution."
                                ],
                                [
                                    "5",
                                    "Exclusion of non-drug causes",
                                    "Viral hepatitis pending; no history/exposure; ultrasound ordered; no ischemic/septic event",
                                    "+1",
                                    "Alternatives considered and largely excluded clinically."
                                ],
                                [
                                    "6",
                                    "Previous information on hepatotoxicity",
                                    "Methotrexate and TMP-SMX both well-known for hepatotoxicity and interaction",
                                    "+2",
                                    "Documented reactions in literature/databases."
                                ],
                                [
                                    "7",
                                    "Response to re-exposure",
                                    "Not applicable (no re-challenge)",
                                    "0",
                                    "\u2014"
                                ]
                            ],
                            "total_score": 7,
                            "causality_category": "Probable"
                        },
                        "ctcae": {
                            "title": "CTCAE Hepatic Toxicity Scoring",
                            "columns": [
                                "Criterion",
                                "Observed / Inferred",
                                "CTCAE Grade",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "ALT/AST",
                                    "Markedly elevated (likely >20\u00d7 ULN)",
                                    "4",
                                    "ALT/AST >20\u00d7 ULN \u2192 life-threatening elevation."
                                ],
                                [
                                    "Total Bilirubin",
                                    "Jaundice evident (likely \u22653\u00d7 ULN; ~\u22653 mg/dL)",
                                    "3\u20134",
                                    "Hyperbilirubinemia with clinical jaundice."
                                ],
                                [
                                    "INR / Coagulopathy",
                                    "Rising INR; impaired synthetic function",
                                    "4",
                                    "Coagulopathy (\u00b1 encephalopathy) consistent with acute liver failure."
                                ],
                                [
                                    "Clinical Presentation",
                                    "Jaundice, asterixis, disorientation (hepatic encephalopathy)",
                                    "4",
                                    "Life-threatening consequences; urgent intervention needed."
                                ]
                            ],
                            "overall_grade": "CTCAE Grade 4 \u2014 Life-threatening; requires urgent intervention"
                        },
                        "reasoning": "The patient developed acute jaundice, confusion, and hepatic tenderness shortly after initiating TMP-SMX (started June 15; symptoms June 20; presentation June 21), a timeline that strongly fits idiosyncratic hepatocellular DILI. There is low likelihood of alternative causes\u2014no fever or hemodynamic instability to suggest ischemic or septic hepatitis, viral panels are pending with low pretest probability, and there is no autoimmune or metabolic history. Mechanistically, TMP-SMX can raise free methotrexate levels and impair folate metabolism; in an older patient with alcohol use (and possible CKD), this pharmacologic interaction plausibly potentiates hepatocellular necrosis and explains concurrent mucosal/CNS findings. The clinical pattern is hepatocellular (expected ALT > AST \u226b ALP) and the presence of encephalopathy with presumed INR >1.5 and elevated bilirubin meets criteria for non-acetaminophen acute liver failure. RUCAM totals 7 (Probable), with TMP-SMX as the primary culprit and methotrexate as a significant co-factor. Immediate management includes withdrawal of both agents, initiation of N-acetylcysteine, aggressive supportive care, and ICU-level monitoring."
                    }
                }
            }
        },
        "createdAt": "2025-10-14T16:50:19.477Z",
        "updatedAt": "2025-10-14T16:50:19.477Z"
    },
    {
        "id": "dashboard-item-1759906246155-lab-table",
        "type": "component",
        "x": 500,
        "y": 4400,
        "width": 520,
        "height": 500,
        "componentType": "LabTable",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Findings",
            "component": "LabTable",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2015-08-10",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2016-02-20",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2018-09-05",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2021-03-15",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2025-06-15",
                        "meta": {
                            "ui_risk_color": "amber"
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2025-06-21",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Suspected DILI",
                                "Potential MTX toxicity",
                                "Acute liver failure risk"
                            ]
                        }
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.155Z",
        "updatedAt": "2025-10-14T16:50:46.155Z"
    },
    {
        "id": "dashboard-item-1759906246156-lab-chart",
        "type": "component",
        "x": 1050,
        "y": 4400,
        "width": 520,
        "height": 500,
        "componentType": "LabChart",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Trends",
            "component": "LabChart",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2015-08-10",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2016-02-20",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2018-09-05",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2021-03-15",
                        "meta": {
                            "ui_risk_color": "green"
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2025-06-15",
                        "meta": {
                            "ui_risk_color": "amber"
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2025-06-21",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Suspected DILI",
                                "Potential MTX toxicity"
                            ]
                        }
                    }
                ],
                "medicationTimeline": [
                    {
                        "name": "Methotrexate",
                        "start": "2015-08-10",
                        "dose": "10mg weekly"
                    },
                    {
                        "name": "Methotrexate",
                        "start": "2018-09-05",
                        "dose": "20mg weekly"
                    },
                    {
                        "name": "Lisinopril",
                        "start": "2018-09-05",
                        "dose": "10mg daily"
                    },
                    {
                        "name": "Trimethoprim-Sulfamethoxazole",
                        "start": "2025-06-15",
                        "end": "2025-06-25",
                        "dose": "800/160mg BID"
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.156Z",
        "updatedAt": "2025-10-14T16:50:46.156Z"
    },
    {
        "id": "dashboard-item-1759906246157-differential-diagnosis",
        "type": "component",
        "x": 1600,
        "y": 4400,
        "width": 520,
        "height": 500,
        "componentType": "DifferentialDiagnosis",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Differential Diagnosis",
            "component": "DifferentialDiagnosis",
            "props": {
                "patientData": {
                    "encounters": [
                        {
                            "encounter_no": 6,
                            "assessment": {
                                "impression": "Acute liver injury likely DILI and/or severe methotrexate toxicity",
                                "differential": [
                                    "Severe methotrexate toxicity (\u00b1 pancytopenia, hepatic/renal injury)",
                                    "TMP-SMX\u2013induced DILI",
                                    "Acute viral hepatitis",
                                    "Acute decompensation of undiagnosed chronic liver disease",
                                    "Sepsis with multiorgan dysfunction"
                                ]
                            },
                            "rucam_ctcae_analysis": {
                                "rucam": {
                                    "rows": [
                                        [
                                            "5",
                                            "Exclusion of non-drug causes",
                                            "viral hepatitis pending",
                                            "+2",
                                            "Awaiting serology"
                                        ]
                                    ]
                                },
                                "reasoning": "no autoimmune or metabolic history; no fever or hemodynamic instability"
                            }
                        }
                    ]
                }
            }
        },
        "createdAt": "2025-10-14T16:50:46.157Z",
        "updatedAt": "2025-10-14T16:50:46.157Z"
    },
    {
        "id": "dashboard-item-1759906300003-single-encounter-1",
        "type": "component",
        "x": -1300,
        "y": 800,
        "width": 400,
        "height": 500,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #1 - Initial Consult",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 1,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2015-08-10T11:00:00",
                        "provider": {
                            "name": "Dr. Elizabeth Hayes",
                            "specialty": "Rheumatology (Initial Consult)"
                        },
                        "ui_risk_color": "green"
                    },
                    "reason_for_visit": "Initial rheumatology consult",
                    "chief_complaint": "Bilateral joint pain and swelling.",
                    "hpi": "53-year-old retired carpenter with 6 months progressive symmetrical small-joint pain/swelling (hands/feet), morning stiffness >60 min, fatigue, limited NSAID relief.",
                    "medications_prior": [
                        {
                            "name": "Ibuprofen",
                            "dose": "200 mg",
                            "route": "PO",
                            "frequency": "PRN",
                            "indication": "Joint pain"
                        }
                    ],
                    "physical_exam": {
                        "general": "Fatigued but comfortable, NAD",
                        "msk": "Bilateral swelling/tenderness MCPs 2-3, PIPs 2-3, MTPs 2-3; synovitis; reduced grip"
                    },
                    "assessment": {
                        "impression": "Seropositive Rheumatoid Arthritis (active)",
                        "differential": [
                            "Psoriatic Arthritis",
                            "Systemic Lupus Erythematosus"
                        ]
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "RF",
                                "Anti-CCP",
                                "CBC",
                                "LFTs"
                            ]
                        },
                        "management": {
                            "medications_started": [
                                {
                                    "name": "Methotrexate",
                                    "dose": "10 mg",
                                    "route": "PO",
                                    "frequency": "weekly"
                                }
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 0,
                "dataSource": "Nervecentre"
            }
        },
        "createdAt": "2025-10-14T16:55:00.003Z",
        "updatedAt": "2025-10-14T16:55:00.003Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-2",
        "type": "component",
        "x": -700,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #2 - Outpatient Review",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 2,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2016-02-20T09:30:00",
                        "provider": {
                            "name": null,
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "green"
                    },
                    "reason_for_visit": "Routine MTX monitoring and RA review",
                    "chief_complaint": "Routine medication monitoring; RA follow-up",
                    "hpi": "Good RA control on MTX 10 mg weekly; no MTX side effects; occasional joint aches; adherent to MTX and folic acid; no new concerns.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "dose": "10 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Paracetamol",
                            "dose": null,
                            "route": "PO",
                            "frequency": "PRN"
                        }
                    ],
                    "physical_exam": {
                        "general": "Well; no jaundice",
                        "msk": "No active synovitis; mild residual hand deformities",
                        "vitals": "BP 132/80, HR 70, RR 16, Temp 36.7\u00b0C"
                    },
                    "assessment": {
                        "impression": "Stable RA on MTX",
                        "differential": []
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "CBC",
                                "LFTs",
                                "Renal function (Creatinine, eGFR)"
                            ]
                        },
                        "management": {
                            "medications_started": [],
                            "education": [
                                "Continue Methotrexate 10 mg weekly and Folic Acid 5 mg weekly",
                                "Strict alcohol avoidance while on MTX",
                                "Smoking cessation encouraged; referral offered"
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 1,
                "dataSource": "Medilogik"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-3",
        "type": "component",
        "x": 0,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #3 - Outpatient (Elevated BP)",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 3,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2018-09-05T10:00:00",
                        "provider": {
                            "name": null,
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "green"
                    },
                    "reason_for_visit": "Routine review; elevated blood pressure",
                    "chief_complaint": "Raised BP readings at home",
                    "hpi": "BP 145\u2013155/90\u201395; asymptomatic. RA well-controlled on MTX 10 mg but specialist advised increase to 20 mg for mild flares. Quit smoking in 2017; continues 1\u20132 beers/day.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "dose": "10 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Paracetamol",
                            "dose": null,
                            "route": "PO",
                            "frequency": "PRN"
                        }
                    ],
                    "physical_exam": {
                        "general": "Well",
                        "vitals": "BP 148/92, HR 72, RR 16, Temp 36.8\u00b0C",
                        "cvs": "Normal S1/S2, no murmurs",
                        "msk": "No active synovitis"
                    },
                    "assessment": {
                        "impression": "New essential hypertension; RA stable; plan MTX dose increase",
                        "differential": []
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "CBC",
                                "LFTs",
                                "Creatinine",
                                "eGFR"
                            ]
                        },
                        "management": {
                            "medications_started": [
                                {
                                    "name": "Lisinopril",
                                    "dose": "10 mg",
                                    "route": "PO",
                                    "frequency": "daily"
                                },
                                {
                                    "name": "Methotrexate",
                                    "dose": "20 mg",
                                    "route": "PO",
                                    "frequency": "weekly"
                                }
                            ],
                            "education": [
                                "Lisinopril side effects (e.g., cough); monitor BP regularly",
                                "Reinforce alcohol moderation with higher MTX dose",
                                "Continue Folic Acid the day after MTX"
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 2,
                "dataSource": "Viper"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-4",
        "type": "component",
        "x": 700,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #4 - Outpatient (Chronic Review)",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 4,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2021-03-15T09:00:00",
                        "provider": {
                            "name": null,
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "green"
                    },
                    "reason_for_visit": "Routine chronic disease review (RA, HTN)",
                    "chief_complaint": "Routine follow-up for RA/HTN",
                    "hpi": "Overall well; RA controlled on MTX 20 mg; BP controlled on Lisinopril; occasional low back pain; eGFR mildly declined but stable; continues 1\u20132 beers/day.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "dose": "20 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly (next day after MTX)"
                        },
                        {
                            "name": "Lisinopril",
                            "dose": "10 mg",
                            "route": "PO",
                            "frequency": "daily"
                        },
                        {
                            "name": "Paracetamol",
                            "dose": null,
                            "route": "PO",
                            "frequency": "PRN"
                        }
                    ],
                    "physical_exam": {
                        "general": "Fit/well",
                        "vitals": "BP 130/82, HR 68, RR 16, Temp 36.7\u00b0C",
                        "msk": "No synovitis",
                        "abdomen": "Soft, non-tender"
                    },
                    "assessment": {
                        "impression": "Stable RA; controlled HTN; chronic mild low back pain; mild CKD (stable)",
                        "differential": []
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "CBC",
                                "LFTs",
                                "Creatinine",
                                "eGFR"
                            ]
                        },
                        "management": {
                            "medications_started": [],
                            "education": [
                                "Continue MTX 20 mg weekly, Folic Acid 5 mg weekly, Lisinopril 10 mg daily",
                                "Hydration importance with CKD and ACE inhibitor",
                                "Alcohol moderation reinforced"
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 3,
                "dataSource": "ICE"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-5",
        "type": "component",
        "x": 1400,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #5 - Outpatient (Sinusitis)",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 5,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2025-06-15T10:30:00",
                        "provider": {
                            "name": null,
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "amber",
                        "ui_flags": [
                            "New potentially hepatotoxic/interactive drug (TMP-SMX) started while on MTX"
                        ]
                    },
                    "reason_for_visit": "Sinusitis symptoms",
                    "chief_complaint": "Facial pain, congestion, purulent nasal discharge",
                    "hpi": "5 days nasal congestion, facial pain, headache, green discharge; worse bending forward; afebrile; RA controlled; adherent to meds; requests antibiotics.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "dose": "20 mg",
                            "route": "PO",
                            "frequency": "weekly with Folic Acid next day"
                        },
                        {
                            "name": "Lisinopril",
                            "dose": "10 mg",
                            "route": "PO",
                            "frequency": "daily"
                        },
                        {
                            "name": "Paracetamol",
                            "dose": null,
                            "route": "PO",
                            "frequency": "PRN"
                        }
                    ],
                    "physical_exam": {
                        "general": "NAD",
                        "ent": "Maxillary tenderness; congested nasal mucosa with mucopurulent discharge; oropharynx clear",
                        "vitals": "BP 135/85, HR 72, RR 16, Temp 37.0\u00b0C"
                    },
                    "assessment": {
                        "impression": "Acute bacterial sinusitis; RA/HTN/CKD stable",
                        "differential": []
                    },
                    "plan": {
                        "investigations": {
                            "labs": []
                        },
                        "management": {
                            "medications_started": [
                                {
                                    "name": "Trimethoprim-Sulfamethoxazole",
                                    "dose": "800/160 mg",
                                    "route": "PO",
                                    "frequency": "BID",
                                    "duration_days": 10
                                }
                            ],
                            "education": [
                                "Potential side effects of TMP-SMX",
                                "Seek care if symptoms worsen or new symptoms develop"
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 4,
                "dataSource": "BigHand"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-6",
        "type": "component",
        "x": 2100,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #6 - Emergency Visit",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 6,
                    "meta": {
                        "visit_type": "ED",
                        "date_time": "2025-06-21T14:00:00",
                        "provider": {
                            "name": "Dr. Sarah Chen",
                            "specialty": "Emergency Medicine"
                        },
                        "ui_risk_color": "red",
                        "event_tags": [
                            "Suspected DILI",
                            "Potential MTX toxicity",
                            "Acute liver failure risk"
                        ]
                    },
                    "reason_for_visit": "Severe fatigue, jaundice, epigastric pain, confusion",
                    "chief_complaint": "Severe fatigue, jaundice, epigastric pain, confusion",
                    "hpi": "63-year-old female with 24h severe fatigue, jaundice, epigastric pain; 4\u20136 days prior noted fatigue, mouth ulcers, nausea; started TMP-SMX 6 days ago for sinusitis",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "dose": "20 mg",
                            "route": "PO",
                            "frequency": "weekly"
                        },
                        {
                            "name": "Trimethoprim-Sulfamethoxazole",
                            "dose": "800/160 mg",
                            "route": "PO",
                            "frequency": "BID"
                        }
                    ],
                    "physical_exam": {
                        "general": "Jaundiced, fatigued, drowsy; disoriented to time/place",
                        "abdomen": "Soft, non-distended; mild epigastric tenderness",
                        "cns": "Arousable; PERL; slow commands; asterixis present; GCS 13"
                    },
                    "assessment": {
                        "impression": "Acute liver injury likely DILI and/or severe methotrexate toxicity",
                        "differential": [
                            "Severe methotrexate toxicity",
                            "TMP-SMX\u2013induced DILI",
                            "Acute viral hepatitis"
                        ]
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "CBC",
                                "CMP",
                                "Methotrexate level (urgent)",
                                "HAV IgM",
                                "HBsAg"
                            ]
                        },
                        "management": {
                            "medications_started": [],
                            "education": [
                                "Immediate ICU admission",
                                "N-acetylcysteine protocol"
                            ]
                        }
                    }
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 53
                },
                "encounterIndex": 5,
                "dataSource": "VueExplore"
            }
        },
        "createdAt": "2025-10-14T16:55:00.004Z",
        "updatedAt": "2025-10-14T16:55:00.004Z"
    },
    {
        "id": "raw-nervecentre-encounter-1",
        "type": "component",
        "x": -2250,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 1",
        "content": {
            "title": "Nervecentre - Encounter 1",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 1,
                "date": "2015-08-10",
                "visitType": "Outpatient Rheumatology",
                "provider": "Dr. Elizabeth Hayes",
                "specialty": "Rheumatology",
                "rawText": "\u2013 2015-08-10, Outpatient Rheumatology (Initial Consult)\nPatient: Sarah Miller, 53-year-old female, retired carpenter.\nClinician: Dr. Elizabeth Hayes, Rheumatology.\nChief Complaint: 6-month history of bilateral hand and foot joint pain/swelling.\nHistory of Present Illness: \u201cProgressive, symmetrical pain and swelling in MCPs and PIPs of both hands and 2nd\u20133rd MTPs of both feet. Severe morning stiffness >1 hour daily and significant fatigue. Tried ibuprofen 200 mg PRN with minimal relief. Symptoms worse in mornings, slightly better with activity. Denies fevers, rash, chest pain, respiratory or GI symptoms, or recent infections.\u201d\nPast Medical History: No liver disease. Appendectomy in childhood. No other chronic illnesses.\nMedication History: Occasional Ibuprofen 200 mg as needed.\nAllergies: None (NKDA).\nFamily History: Father with hypertension and type 2 diabetes; mother with osteoarthritis. No known autoimmune or liver disease in family.\nSocial History: Drinks ~1\u20132 beers/day (7\u201314 units/week) routinely; denies bingeing. Smokes ~1 pack/day (35 pack-year history). Retired carpenter (exposure to wood dust/solvents). No IV drug use. Married, monogamous.\nReview of Systems: Negative for weight loss, fever, or rash. Cardiac and respiratory: no chest pain or cough. GI: no nausea/vomiting/diarrhea. Neuro: no headaches or focal deficits. MSK: (as above).\nPhysical Exam: Alert, fatigued but NAD. Vitals WNL. HEENT normal. Neck supple, no lymphadenopathy. Heart: RRR, no murmurs. Lungs clear. Abdomen soft, NTND, no hepatosplenomegaly. Skin: no rash or jaundice. MSK: Hands \u2013 visibly swollen, tender MCP joints (2nd\u20133rd) and PIP joints (2nd\u20133rd) bilaterally; similar swelling in both 2nd\u20133rd MTP joints. Palpable synovitis and warmth. Reduced grip strength. Range-of-motion limited by pain. No joint deformities yet. No subcutaneous nodules.\nAssessment: Likely Seropositive Rheumatoid Arthritis, active. Differential: Psoriatic arthritis, SLE, gout/pseudogout.\nPlan:\nInvestigations: Order Rheumatoid Factor, anti-CCP IgG, ESR, CRP, CBC with diff, LFTs (AST, ALT, ALP, bilirubin), creatinine/eGFR, Hep B serologies (HBsAg, anti-HBc total) and Hep C antibody.\nMedications: Start Methotrexate 10 mg PO once weekly + Folic Acid 5 mg PO weekly (to be taken the day after MTX). Discuss MTX side effects.\nPatient Education: Explained RA pathophysiology, chronic nature, and treatment goals. Counseling on MTX: common side effects (malaise, GI upset, mucositis) and serious risks (hepatotoxicity, bone marrow suppression, lung toxicity). Emphasized need for strict alcohol avoidance with MTX. Advised regular blood test monitoring. Reinforced smoking cessation (\u201cgreatest modifiable risk\u201d).\nReferrals: Rheumatology nurse to provide MTX information/monitoring. Smoking cessation support provided.\nFollow-Up: Return to Rheumatology clinic in 3 months. GP to check CBC, LFTs, renal, ESR/CRP in 4 weeks. \u201cRed flag\u201d symptoms (fever, severe fatigue, rash, jaundice) to prompt urgent evaluation.\nCoding: ICD-10 M05.9 (Seropositive RA, unspecified); CPT 99204 (New patient, moderate complexity).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-nervecentre-encounter-2",
        "type": "component",
        "x": -1650,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 2",
        "content": {
            "title": "Nervecentre - Encounter 2",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 2,
                "date": "2016-02-20",
                "visitType": "Outpatient GP",
                "rawText": "\u2013 2016-02-20, Outpatient GP (Methotrexate Monitoring)\nPatient: Same.\nPurpose: Routine RA follow-up and MTX monitoring.\nHistory: Patient reports much better. Joint pain/stiffness mostly resolved on MTX 10 mg weekly. \u201cNo mouth sores or nausea. Feels more energetic.\u201d Occasional mild ache, no synovitis. Adherent with MTX and folate. Denies new meds or problems.\nMedications: Methotrexate 10 mg/WK, Folic Acid 5 mg/WK, Paracetamol PRN.\nSocial Update: Drinks only on weekends (~4\u20138 units/week); counselled to avoid alcohol entirely while on MTX. Still smokes ~15 cigarettes/day; smoking cessation counseling repeated. Offered quit-smoking program referral. No changes in occupation.\nPhysical Exam: Well-appearing, no jaundice. MSK: Hands \u2013 no tender or swollen joints; mild previous ulnar deviation. Vitals: BP 132/80, HR 70, afebrile. Lungs & heart normal. Abdomen NT, no edema.\nAssessment: Stable Rheumatoid Arthritis on MTX.\nPlan: Continue Methotrexate 10 mg weekly + Folic Acid 5 mg. Lab orders for today: CBC with diff, LFTs, creatinine (MTX monitoring). Reinforce strict alcohol abstinence and smoking cessation. Next review in 3 months or as needed.\nCoding: SNOMED 69896004 (Rheumatoid arthritis).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-nervecentre-encounter-3",
        "type": "component",
        "x": -1050,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 3",
        "content": {
            "title": "Nervecentre - Encounter 3",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 3,
                "date": "2018-09-05",
                "visitType": "Outpatient GP",
                "rawText": "\u2013 2018-09-05, Outpatient GP (Routine Check \u2013 Hypertension Noted)\nPurpose: Routine chronic disease check (RA follow-up) with incidental hypertension noted. Rheum had suggested increasing MTX dose due to mild flares. Patient quit smoking in 2017 (20 PY total). Reports 1\u20132 beers/day.\nMedications: Methotrexate 10 mg/WK, Folic Acid 5 mg/WK, Paracetamol PRN.\nSocial History: Alcohol ~7\u201314 units/week. Smoking ceased in 2017.\nExam: Vitals: BP 148/92, HR 72, afebrile. Heart & lungs normal. MSK: no active synovitis. Abdomen soft, NT.\nAssessment: New Essential Hypertension. RA remains quiescent but consider MTX uptitration soon.\nPlan: Start Lisinopril 10 mg PO daily for BP. Increase Methotrexate to 20 mg weekly (adjust prescription accordingly) with continued Folic Acid 5 mg. Repeat CBC/LFTs/renal in 4 weeks. Counsel on Lisinopril potential cough. Continue alcohol moderation advice. Follow up in 4 weeks for hypertension and MTX response.\nCoding: SNOMED 383410000 (Essential hypertension), 69896004 (Rheumatoid arthritis).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-nervecentre-encounter-4",
        "type": "component",
        "x": -450,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 4",
        "content": {
            "title": "Nervecentre - Encounter 4",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 4,
                "date": "2021-03-15",
                "visitType": "Outpatient GP",
                "rawText": "\u2013 2021-03-15, Outpatient GP (Chronic Disease Review)\nPurpose: 3-year rheum/HTN/CKD review. Patient feels well. No RA flares on MTX 20 mg weekly. BP controlled on Lisinopril. Complains of mild chronic low back pain (managed with exercise and Occasional paracetamol). Continues to drink 1\u20132 beers/day, has felt healthy otherwise.\nMedications: Methotrexate 20 mg/WK, Folic Acid 5 mg/WK, Lisinopril 10 mg daily, Paracetamol PRN.\nSocial History: Alcohol ~7\u201314 units/week. Smoking quit since 2017.\nExam: Fit appearing. Vitals: BP 130/82, HR 68, afebrile. MSK: No active synovitis; joints stable. Abdomen soft, NT; no edema.\nAssessment: Chronic stable conditions: Rheumatoid arthritis (controlled), Hypertension (controlled), Mild chronic low back pain, Stage 3 CKD (eGFR ~55, stable).\nPlan: Continue all current medications. Routine labs ordered: CBC, LFTs, creatinine, eGFR. Advise hydration (due to CKD/ACEi) and maintain limited alcohol. Discuss low back care (exercise/OTC pain relief). Next review in 6 months unless problems.\nCoding: SNOMED 69896004 (Rheumatoid arthritis), 383410000 (Hypertension), 23643009 (Chronic kidney disease, mild).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-nervecentre-encounter-5",
        "type": "component",
        "x": 150,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 5",
        "content": {
            "title": "Nervecentre - Encounter 5",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 5,
                "date": "2025-06-15",
                "visitType": "Outpatient GP",
                "rawText": "\u2013 2025-06-15, Outpatient GP (Sinusitis Symptoms)\nPurpose: Patient reports 5 days of sinus congestion/headache. Fever absent. He believes \u201ccold\u201d is persistent; requested antibiotics. No new issues otherwise; RA stable.\nMedications: Methotrexate 20 mg/WK (Mon), Folic Acid 5 mg (Tue), Lisinopril 10 mg daily, Paracetamol PRN.\nSocial History: Alcohol 7\u201314 units/week, no recent changes. Ex-smoker (quit 2017, 20 PY).\nExam: Well. ENT: forehead pain on palpation; nasal mucosa red, green discharge. Oropharynx clear. No sinus tenderness except maxillary. Vitals: BP 135/85, T 37.0\u00b0C, SpO\u2082 98%.\nAssessment/Plan: Likely Acute Bacterial Sinusitis. Prescribe Trimethoprim/Sulfa DS 800/160 mg PO BID \u00d710 days. Advise symptomatic care (saline spray, steam, analgesia). Warn to complete ABX and seek care if worsens or new symptoms. Continue RA/HTN meds unchanged. Review if symptoms persist.\nCoding: SNOMED 22285007 (Acute sinusitis).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-nervecentre-encounter-6",
        "type": "component",
        "x": 750,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Nervecentre EPR data for Encounter 6",
        "content": {
            "title": "Nervecentre - Encounter 6",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 6,
                "date": "2025-06-21",
                "visitType": "Emergency Dept",
                "provider": "Dr. Sarah Chen",
                "specialty": "Emergency Medicine",
                "rawText": "\u2013 2025-06-21, Emergency Dept (Severe Jaundice & Fatigue)\nPatient: Sarah Miller, 63 y/o. Brought in by wife for acute jaundice, confusion, and epigastric pain.\nClinician: Dr. Sarah Chen, Emergency Medicine.\nPresenting Complaint: 24-hour history of extreme tiredness, yellow eyes/skin, upper abdomen pain, nausea. Recent TMP-SMX for sinusitis (started 6 days ago). Mild mouth ulcers noted 4\u20136 days ago. No fever or GI bleeding. No other new meds.\nPast History: Rheumatoid arthritis (10 years, on MTX), Hypertension (7 years), chronic back pain, CKD Stage 3 (eGFR ~55). No known liver disease. Appendectomy as a child.\nMedications: MTX 20 mg weekly (Mon), Folic Acid 5 mg weekly (Tue), Lisinopril 10 mg daily, TMP-SMX 800/160 mg BID \u00d76d, Paracetamol PRN. Allergies: Penicillin (rash).\nReview of Systems: Significant for nausea, anorexia, dark urine. No cough/dyspnea. Altered mental status (mild confusion).\nPhysical Exam: Ill, jaundiced, drowsy (GCS 13). Vitals: BP 142/90, HR 75, RR 18, T 36.9\u00b0C. Neuro: Arousable but disoriented; asterixis present. Abd: Soft, mild epigastric tenderness, no HSM or ascites. Skin: Generalized icterus, oral mucosa with small ulcers. No rash or bruises.\nImpression: Acute severe liver injury (likely drug-induced: MTX toxicity \u00b1 TMP-SMX). Possible methotrexate overdose or fulminant hepatitis. DDX: acute viral hepatitis, Wilson\u2019s, sepsis.\nPlan: Admit to ICU. STAT labs: CBC (for cytopenias), Comprehensive Metabolic Panel (LFTs, renal), PT/INR, Ammonia, Serum MTX level, viral hepatitis serologies (HAV IgM, HBsAg/IgM, HCV Ab), autoimmune serologies, toxicology. STAT abdominal ultrasound (liver appearance, biliary). Start IV fluids and IV N-acetylcysteine (covering for DILI/acute liver failure). NPO, frequent neuro checks. Notify GI/Hepatology and Hematology. Prepare for possible transfusions or dialysis.\nOrders/Results: (via ICE/EHR) STAT lab draw sent.\nCoding: ICD-10 K71.1 (Toxic liver disease with hepatic necrosis), T45.1X5A (Adverse effect of MTX), T36.0X5A (Adverse effect of sulfonamides). CPT 99285 (ED high complexity).",
                "dataSource": "Nervecentre EPR"
            }
        },
        "createdAt": "2025-10-17T03:32:13.025Z",
        "updatedAt": "2025-10-17T03:32:13.025Z"
    },
    {
        "id": "raw-medilogik-ems-colonoscopy",
        "type": "component",
        "x": 850,
        "y": -2600,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Medilogik EMS endoscopy report",
        "content": {
            "title": "Medilogik EMS - Colonoscopy",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 0,
                "date": "2023-11-10",
                "visitType": "Colonoscopy",
                "provider": "Dr. Alice N. Wong",
                "specialty": "Endoscopy",
                "rawText": "Medilogik EMS (Endoscopy Report)\n(Example endoscopy procedure report using Medilogik\u2019s structured format)\nPatient: Sarah Miller (63F), MRN 12345678.\nProcedure: Colonoscopy on 2023-11-10 08:30 (Endoscopy Suite). Endoscopist: Dr. Alice N. Wong.\nIndication: Iron-deficiency anemia (chronic); screening given age and methotrexate use.\nSedation: IV Midazolam and Fentanyl; monitored anesthesia care.\nFindings: Traversed to cecum. Colonic mucosa has scattered diverticula in sigmoid. One 5 mm sessile polyp in sigmoid colon (25 cm from anal verge). No evidence of colitis or masses. Terminal ileum intubated, unremarkable. Visualized upper GI (if dual-scope done): unremarkable esophagus, stomach, duodenum (if applicable).\nInterventions: Polypectomy performed with cold biopsy forceps; specimen sent to pathology. Biopsies of normal-appearing mucosa not taken. Bowel prep good.\nImages: [Endoscopic snapshot of the sigmoid polyp] (attached to report).\nConclusions/Plan: Small adenomatous polyp removed (histology pending). No malignant lesions seen. Diverticulosis noted. Recommend routine surveillance colonoscopy in 10 years per guidelines. Follow-up GI clinic after pathology.\nQuality Metrics: Procedure time, withdrawal time 6 min, sedation doses recorded. Saved diverticulosis and polyp data for audit/compliance to national standards.\n(This report demonstrates Medilogik\u2019s endoscopy workflow fields and structured findings.)\n",
                "dataSource": "Medilogik EMS"
            }
        },
        "createdAt": "2025-10-17T03:44:32.506Z",
        "updatedAt": "2025-10-17T03:44:32.507Z"
    },
    {
        "id": "raw-viper-ultrasound-ivc",
        "type": "component",
        "x": 160,
        "y": -2600,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "Raw Viper ultrasound IVC assessment",
        "content": {
            "title": "Viper - IVC Ultrasound",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 0,
                "date": "2025-06-21",
                "visitType": "IVC Ultrasound (Point-of-Care)",
                "provider": "Dr. Sarah Chen",
                "specialty": "Emergency Medicine",
                "rawText": "VIPER Ultrasound (ICU/ED Point-of-Care)\nDate/Time: 2025-06-21 15:30 (ED/ICU).\nOperator: Dr. Sarah Chen (Emergency Medicine).\nProcedure: Ultrasound of Inferior Vena Cava (IVC) \u2013 Subxiphoid long-axis.\nFindings (VIPER quantitative analysis):\nIVC diameter on inspiration: 2.0 cm\nIVC diameter on expiration: 2.3 cm\nIVC Collapsibility Index: 13% (insp/exp variation)\nInterpretation: IVC minimally collapsible; suggests normal to increased intravascular volume. No significant hypovolemia.\nClinical Use: Results used to guide fluid management. (In this case, moderate fluids given carefully as patient shows probable volume repletion.)\n(VIPER\u2019s automated analysis provides objective IVC measurements and a quick interpretation to optimize fluid therapy decisions.)\n",
                "dataSource": "VIPER Ultrasound"
            }
        },
        "createdAt": "2025-10-17T03:49:53.778Z",
        "updatedAt": "2025-10-17T03:49:53.779Z"
    },
    {
        "id": "raw-bighand-dictation-hayes-2015",
        "type": "component",
        "x": 1600,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "BigHand dictation from Dr. Elizabeth Hayes (Rheumatology)",
        "content": {
            "title": "BigHand - Dr. Hayes Dictation",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 1,
                "date": "2015-08-10",
                "visitType": "Rheumatology Initial Consult",
                "provider": "Dr. Elizabeth Hayes",
                "specialty": "Rheumatology",
                "rawText": "BigHand Dictation (Transcribed Notes)\nDictation \u2013 Dr. Elizabeth Hayes (Rheumatology), 2015-08-10:\n\"Ms. Sarah Miller is a 63-year-old retired carpenter with a six-month history of progressive, symmetrical arthritis. He has pain and swelling in the small joints of his hands and feet, accompanied by morning stiffness over one hour. He reports significant fatigue. He has no fevers, rash, or other systemic symptoms and has only had minimal relief with ibuprofen 200 mg PRN. On exam, there is swelling and tenderness of MCPs and PIPs bilaterally and of the 2nd\u20133rd MTP joints. Grip strength is reduced. No skin lesions or organomegaly. My impression is active seropositive rheumatoid arthritis. Plan: order Rheumatoid Factor and anti-CCP, ESR, CRP, CBC, LFTs, creatinine, and hepatitis serologies. Start Methotrexate 10 mg weekly with folic acid. Counsel patient on MTX side effects and necessity of regular labs and alcohol avoidance.\"\n(BigHand would queue each dictation for transcription and signature, and track completion of related tasks.)",
                "dataSource": "BigHand Dictation"
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-bighand-dictation-green-2021",
        "type": "component",
        "x": 2175,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "BigHand dictation from Dr. Emily Green (GP)",
        "content": {
            "title": "BigHand - Dr. Green Dictation",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 4,
                "date": "2021-03-15",
                "visitType": "General Practice",
                "provider": "Dr. Emily Green",
                "specialty": "General Practice",
                "rawText": "BigHand Dictation (Transcribed Notes)\nDictation \u2013 Dr. Emily Green (GP), 2021-03-15:\n\"Mr. McAllister is a 63-year-old female with longstanding rheumatoid arthritis on methotrexate 20 mg weekly and hypertension on lisinopril 10 mg daily. He feels well. Blood pressure and arthritis are well controlled. There are no new complaints except a mild chronic low back ache. Exam today is unremarkable with no synovitis. Plan is to continue all current medications, order routine labs (CBC, LFT, renal) and advise continued moderation of alcohol. Reinforce follow-up in six months. Smoking cessation remains important.\"\n(BigHand would queue each dictation for transcription and signature, and track completion of related tasks.)",
                "dataSource": "BigHand Dictation"
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-bighand-dictation-chen-2025",
        "type": "component",
        "x": 2750,
        "y": -4700,
        "width": 480,
        "height": 700,
        "componentType": "RawClinicalNote",
        "color": "#ffffff",
        "description": "BigHand dictation from Dr. Sarah Chen (Emergency)",
        "content": {
            "title": "BigHand - Dr. Chen Dictation",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 6,
                "date": "2025-06-21",
                "visitType": "Emergency Medicine",
                "provider": "Dr. Sarah Chen",
                "specialty": "Emergency Medicine",
                "rawText": "BigHand Dictation (Transcribed Notes)\nDictation \u2013 Dr. Sarah Chen (Emergency), 2025-06-21:\n\"Patient is a 63-year-old man with a history of rheumatoid arthritis and hypertension, presenting with one day of jaundice, confusion, and epigastric pain. He started trimethoprim-sulfamethoxazole 6 days ago. Labs show acute liver failure with AST/ALT ~ 1500, INR elevated, and pancytopenia (WBC and platelets very low). Differential includes methotrexate toxicity versus TMP-SMX hepatotoxicity. Admitting to ICU. Orders: admit to ICU, start IV fluids and N-acetylcysteine, urgent labs including CBC, CMP, coags, hepatitis panel, toxicology, and abdominal ultrasound. Consult GI and hematology.\"\n(BigHand would queue each dictation for transcription and signature, and track completion of related tasks.)",
                "dataSource": "BigHand Dictation"
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-ice-lab-data-encounter-1",
        "type": "component",
        "x": -2300,
        "y": -2600,
        "width": 400,
        "height": 600,
        "componentType": "ICELabData",
        "color": "#ffffff",
        "description": "ICE Laboratory System - Encounter 1 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 1",
            "component": "ICELabData",
            "props": {
                "encounters": [
                    {
                        "encounter": 1,
                        "tests": [
                            {
                                "name": "ESR",
                                "result": 45,
                                "unit": "mm/hr",
                                "reference_range": "0 - 20",
                                "flag": "H"
                            },
                            {
                                "name": "CRP",
                                "result": 25,
                                "unit": "mg/L",
                                "reference_range": "<5",
                                "flag": "H"
                            },
                            {
                                "name": "Rheumatoid Factor",
                                "result": 120,
                                "unit": "IU/mL",
                                "reference_range": "<14",
                                "flag": "H"
                            },
                            {
                                "name": "Anti-CCP",
                                "result": ">200",
                                "unit": "U/mL",
                                "reference_range": "<20",
                                "flag": "H"
                            },
                            {
                                "name": "WBC",
                                "result": 7.5,
                                "unit": "x10^9/L",
                                "reference_range": "4.0 - 10.0",
                                "flag": ""
                            },
                            {
                                "name": "Hemoglobin",
                                "result": 14.2,
                                "unit": "g/dL",
                                "reference_range": "13.5 - 17.5",
                                "flag": ""
                            },
                            {
                                "name": "Platelets",
                                "result": 280,
                                "unit": "x10^9/L",
                                "reference_range": "150 - 450",
                                "flag": ""
                            },
                            {
                                "name": "Creatinine",
                                "result": 0.9,
                                "unit": "mg/dL",
                                "reference_range": "0.7 - 1.3",
                                "flag": ""
                            },
                            {
                                "name": "eGFR",
                                "result": 85,
                                "unit": "mL/min/1.73m2",
                                "reference_range": ">60",
                                "flag": ""
                            },
                            {
                                "name": "Total Bilirubin",
                                "result": 0.7,
                                "unit": "mg/dL",
                                "reference_range": "0.2 - 1.2",
                                "flag": ""
                            },
                            {
                                "name": "ALT (SGPT)",
                                "result": 25,
                                "unit": "U/L",
                                "reference_range": "7.0 - 56",
                                "flag": ""
                            },
                            {
                                "name": "AST (SGOT)",
                                "result": 22,
                                "unit": "U/L",
                                "reference_range": "8.0 - 40",
                                "flag": ""
                            },
                            {
                                "name": "Alkaline Phosphatase",
                                "result": 90,
                                "unit": "U/L",
                                "reference_range": "40 - 150",
                                "flag": ""
                            },
                            {
                                "name": "HBsAg",
                                "result": "Negative",
                                "unit": "",
                                "reference_range": "Negative",
                                "flag": ""
                            },
                            {
                                "name": "Anti-HBc Total",
                                "result": "Negative",
                                "unit": "",
                                "reference_range": "Negative",
                                "flag": ""
                            },
                            {
                                "name": "Anti-HCV",
                                "result": "Negative",
                                "unit": "",
                                "reference_range": "Negative",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-ice-lab-data-encounter-2",
        "type": "component",
        "x": -1850,
        "y": -2600,
        "width": 400,
        "height": 600,
        "componentType": "ICELabData",
        "color": "#ffffff",
        "description": "ICE Laboratory System - Encounter 2 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 2",
            "component": "ICELabData",
            "props": {
                "encounters": [
                    {
                        "encounter": 2,
                        "tests": [
                            {
                                "name": "WBC",
                                "result": 6.8,
                                "unit": "x10^9/L",
                                "reference_range": "4.0 - 10.0",
                                "flag": ""
                            },
                            {
                                "name": "Hemoglobin",
                                "result": 13.8,
                                "unit": "g/dL",
                                "reference_range": "13.5 - 17.5",
                                "flag": ""
                            },
                            {
                                "name": "Platelets",
                                "result": 265,
                                "unit": "x10^9/L",
                                "reference_range": "150 - 450",
                                "flag": ""
                            },
                            {
                                "name": "Creatinine",
                                "result": 1,
                                "unit": "mg/dL",
                                "reference_range": "0.7 - 1.3",
                                "flag": ""
                            },
                            {
                                "name": "eGFR",
                                "result": 78,
                                "unit": "mL/min/1.73m2",
                                "reference_range": ">60",
                                "flag": ""
                            },
                            {
                                "name": "Total Bilirubin",
                                "result": 0.8,
                                "unit": "mg/dL",
                                "reference_range": "0.2 - 1.2",
                                "flag": ""
                            },
                            {
                                "name": "ALT (SGPT)",
                                "result": 30,
                                "unit": "U/L",
                                "reference_range": "7.0 - 56",
                                "flag": ""
                            },
                            {
                                "name": "AST (SGOT)",
                                "result": 25,
                                "unit": "U/L",
                                "reference_range": "8.0 - 40",
                                "flag": ""
                            },
                            {
                                "name": "Alkaline Phosphatase",
                                "result": 105,
                                "unit": "U/L",
                                "reference_range": "40 - 150",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-ice-lab-data-encounter-3",
        "type": "component",
        "x": -1400,
        "y": -2600,
        "width": 400,
        "height": 600,
        "componentType": "ICELabData",
        "color": "#ffffff",
        "description": "ICE Laboratory System - Encounter 3 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 3",
            "component": "ICELabData",
            "props": {
                "encounters": [
                    {
                        "encounter": 3,
                        "tests": [
                            {
                                "name": "WBC",
                                "result": 7.2,
                                "unit": "x10^9/L",
                                "reference_range": "4.0 - 10.0",
                                "flag": ""
                            },
                            {
                                "name": "Hemoglobin",
                                "result": 14,
                                "unit": "g/dL",
                                "reference_range": "13.5 - 17.5",
                                "flag": ""
                            },
                            {
                                "name": "Platelets",
                                "result": 270,
                                "unit": "x10^9/L",
                                "reference_range": "150 - 450",
                                "flag": ""
                            },
                            {
                                "name": "Creatinine",
                                "result": 1.1,
                                "unit": "mg/dL",
                                "reference_range": "0.7 - 1.3",
                                "flag": ""
                            },
                            {
                                "name": "eGFR",
                                "result": 65,
                                "unit": "mL/min/1.73m2",
                                "reference_range": ">60",
                                "flag": ""
                            },
                            {
                                "name": "Total Bilirubin",
                                "result": 0.9,
                                "unit": "mg/dL",
                                "reference_range": "0.2 - 1.2",
                                "flag": ""
                            },
                            {
                                "name": "ALT (SGPT)",
                                "result": 35,
                                "unit": "U/L",
                                "reference_range": "Jul-56",
                                "flag": ""
                            },
                            {
                                "name": "AST (SGOT)",
                                "result": 30,
                                "unit": "U/L",
                                "reference_range": "Oct-40",
                                "flag": ""
                            },
                            {
                                "name": "Alkaline Phosphatase",
                                "result": 110,
                                "unit": "U/L",
                                "reference_range": "40 - 150",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-ice-lab-data-encounter-5",
        "type": "component",
        "x": -950,
        "y": -2600,
        "width": 400,
        "height": 600,
        "componentType": "ICELabData",
        "color": "#ffffff",
        "description": "ICE Laboratory System - Encounter 5 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 5",
            "component": "ICELabData",
            "props": {
                "encounters": [
                    {
                        "encounter": 5,
                        "tests": [
                            {
                                "panel": "Complete Blood Count",
                                "name": "WBC",
                                "result": 6.5,
                                "unit": "x10^9/L",
                                "reference_range": "4.0 - 10.0",
                                "flag": ""
                            },
                            {
                                "panel": "Complete Blood Count",
                                "name": "Hemoglobin",
                                "result": 13.5,
                                "unit": "g/dL",
                                "reference_range": "13.5 - 17.5",
                                "flag": ""
                            },
                            {
                                "panel": "Complete Blood Count",
                                "name": "Platelets",
                                "result": 250,
                                "unit": "x10^9/L",
                                "reference_range": "150 - 450",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Creatinine",
                                "result": 1.4,
                                "unit": "mg/dL",
                                "reference_range": "0.7 - 1.3",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "eGFR",
                                "result": 58,
                                "unit": "mL/min/1.73m2",
                                "reference_range": ">60",
                                "flag": "L"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Total Bilirubin",
                                "result": 0.9,
                                "unit": "mg/dL",
                                "reference_range": "0.2 - 1.2",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "ALT (SGPT)",
                                "result": 40,
                                "unit": "U/L",
                                "reference_range": "7.0 - 56",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "AST (SGOT)",
                                "result": 35,
                                "unit": "U/L",
                                "reference_range": "8.0 - 40",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Alkaline Phosphatase",
                                "result": 120,
                                "unit": "U/L",
                                "reference_range": "40 - 150",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "raw-ice-lab-data-encounter-6",
        "type": "component",
        "x": -500,
        "y": -2600,
        "width": 400,
        "height": 600,
        "componentType": "ICELabData",
        "color": "#ffffff",
        "description": "ICE Laboratory System - Encounter 6 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 6",
            "component": "ICELabData",
            "props": {
                "encounters": [
                    {
                        "encounter": 6,
                        "tests": [
                            {
                                "panel": "Complete Blood Count",
                                "name": "WBC",
                                "result": 5,
                                "unit": "x10^9/L",
                                "reference_range": "4.0 - 10.0",
                                "flag": ""
                            },
                            {
                                "panel": "Complete Blood Count",
                                "name": "Hemoglobin",
                                "result": 14.5,
                                "unit": "g/dL",
                                "reference_range": "13.5 - 17.5",
                                "flag": ""
                            },
                            {
                                "panel": "Complete Blood Count",
                                "name": "Platelets",
                                "result": 165,
                                "unit": "x10^9/L",
                                "reference_range": "150 - 450",
                                "flag": ""
                            },
                            {
                                "panel": "Complete Blood Count",
                                "name": "Neutrophils",
                                "result": 2.2,
                                "unit": "x10^9/L",
                                "reference_range": "2.0 - 7.5",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Sodium",
                                "result": 138,
                                "unit": "mmol/L",
                                "reference_range": "135 - 145",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Potassium",
                                "result": 5.1,
                                "unit": "mmol/L",
                                "reference_range": "3.5 - 5.0",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Creatinine",
                                "result": 1.5,
                                "unit": "mg/dL",
                                "reference_range": "0.7 - 1.3",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "BUN",
                                "result": 19,
                                "unit": "mg/dL",
                                "reference_range": "20 - 25",
                                "flag": ""
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "eGFR",
                                "result": 58,
                                "unit": "mL/min/1.73m2",
                                "reference_range": ">60",
                                "flag": "L"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Total Bilirubin",
                                "result": 12.5,
                                "unit": "mg/dL",
                                "reference_range": "0.2 - 1.2",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Direct Bilirubin",
                                "result": 8.9,
                                "unit": "mg/dL",
                                "reference_range": "<0.3",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "ALT (SGPT)",
                                "result": 1650,
                                "unit": "U/L",
                                "reference_range": "7.0 - 56",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "AST (SGOT)",
                                "result": 2100,
                                "unit": "U/L",
                                "reference_range": "8.0 - 40",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Alkaline Phosphatase",
                                "result": 350,
                                "unit": "U/L",
                                "reference_range": "40 - 150",
                                "flag": "H"
                            },
                            {
                                "panel": "Comprehensive Metabolic Panel",
                                "name": "Albumin",
                                "result": 3.8,
                                "unit": "g/dL",
                                "reference_range": "3.5 - 5.5",
                                "flag": ""
                            },
                            {
                                "panel": "Coagulation Panel",
                                "name": "PT",
                                "result": 11,
                                "unit": "seconds",
                                "reference_range": "10.0 - 13.0",
                                "flag": ""
                            },
                            {
                                "panel": "Coagulation Panel",
                                "name": "INR",
                                "result": 1,
                                "unit": "",
                                "reference_range": "0.8 - 1.2",
                                "flag": ""
                            },
                            {
                                "panel": "Coagulation Panel",
                                "name": "PTT",
                                "result": 28,
                                "unit": "seconds",
                                "reference_range": "25.0 - 35.0",
                                "flag": ""
                            },
                            {
                                "panel": "Other",
                                "name": "Ammonia",
                                "result": 18,
                                "unit": "umol/L",
                                "reference_range": "11.0 - 32",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        },
        "createdAt": "2025-10-17T12:00:00.000Z",
        "updatedAt": "2025-10-17T12:00:00.000Z"
    },
    {
        "id": "iframe-item-easl-interface",
        "type": "iframe",
        "x": 2700,
        "y": 7100,
        "width": 1800,
        "height": 1200,
        "title": "EASL Web Interface",
        "iframeUrl": "https://easl-board.vercel.app/",
        "color": "#ffffff",
        "rotation": 0,
        "conversationHistory": [
            {
                "id": "conv-1763135822725",
                "query": "Sarah Miller, a 63-year-old female with a history of rheumatoid arthritis treated with methotrexate, essential hypertension managed with lisinopril, and mild chronic kidney disease, presented to the emergency department with severe fatigue, jaundice, epigastric pain, and confusion six days after starting trimethoprim-sulfamethoxazole for acute bacterial sinusitis. Examination revealed jaundice, drowsiness, disorientation, and asterixis. Lab results showed ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and alkaline phosphatase 350 U/L. Can you make a daily diagnostic based on EASL guidelines?",
                "response": "## Medical Reasoning\n\n**Analyzing Patient Symptoms**\n\nI'm currently focused on the patient's symptoms: severe fatigue, jaundice, epigastric pain, and confusion. Six days post-trimethoprim-sulfamethoxazole is crucial context. I'm prioritizing differential diagnoses based on EASL guidelines, exploring possible drug-induced liver injury, and potential complications.\n\n\n**Reviewing Medication History**\n\nMy analysis continues, now zeroing in on the medication history: trimethoprim-sulfamethoxazole's DILI potential is being scrutinized. Methotrexate use for rheumatoid arthritis, plus antihypertensives for essential hypertension, are also on the table. The patient's mild chronic kidney disease adds another layer of complexity.\n\n\n**Assessing DILI Possibilities**\n\nThe focus is now squarely on the patient's presentation and lab findings. I'm actively applying EASL guidelines to determine the likelihood of trimethoprim-sulfamethoxazole-induced liver injury, given the elevated ALT, AST, bilirubin, and alkaline phosphatase, alongside signs of hepatic encephalopathy. The R-ratio calculation is underway, and I'm prepared to evaluate the severity.\n\n\n<RESPONSE>\n\n<QUESTION>\n    - Classify the question type: Diagnosis, Classification, Severity Assessment.\n    - Identify the **clinical intent**: To establish a daily diagnostic for acute liver injury, including identifying the likely cause, classifying the pattern of injury, and assessing its severity, based on EASL guidelines.\n    - Planthe steps required to answer:\n        1.  Confirm suspicion of Drug-Induced Liver Injury (DILI) based on patient history and presentation.\n        2.  Identify the implicated drug and its known association with DILI.\n        3.  Calculate the R-ratio (ALT/ULN / ALP/ULN) to classify the pattern of liver injury (hepatocellular, cholestatic, or mixed).\n        4.  Assess the severity of DILI based on clinical symptoms (jaundice, encephalopathy) and laboratory parameters.\n        5.  Acknowledge the need to exclude alternative causes, as per DILI diagnostic principles.\n        6.  Consider patient comorbidities and co-medications as potential risk factors or confounders.\n    - Indicate the expected \"thinking intensity\": full\n</QUESTION>\n\n<THINKING>\n\n<PATIENT_CONTEXT>\nSarah Miller is a 63-year-old female presentingwith acute liver injury symptoms including severe fatigue, jaundice, epigastric pain, and confusion, developing six days after initiating trimethoprim-sulfamethoxazole. Her laboratory values show significantly elevated ALT (1650 U/L), AST (2100 U/L), total bilirubin (12.5 mg/dL), and alkaline phosphatase (350 U/L). Clinically, she exhibits drowsiness, disorientation, and asterixis, indicative of hepatic encephalopathy. Her medical history includes rheumatoid arthritis treated with methotrexate, essential hypertension on lisinopril, and mild chronic kidney disease. The provided multiparametric assessment thresholdsare not directly applicable for diagnosing DILI or classifying its pattern/severity, as they are primarily for preoperative assessment variables for liver resection (e.g., ALBI grade, APRI, HVPG, ICG-R15, MELD, Milan Criteria). However, the presence of jaundice and encephalopathy arecritical for DILI severity assessment. The elevated transaminases and bilirubin clearly exceed typical ULN values, indicating significant liver damage. The rapid onset after a new medication points strongly towards DILI.\n</PATIENT_CONTEXT>\n\n<DIVERGENT>\n            <strategic_thinking_statement>The clinical intent is to diagnose the cause, pattern, and severity of acute liver injury in this patient. The key patient anchors are the acute onset of symptoms (fatigue, jaundice, epigastric pain, confusion), recent initiation of trimethoprim-sulfamethoxazole, and significantly elevated liver enzymes with signsof encephalopathy. The approach will involve first confirming DILI as the likely etiology, then classifying the injury pattern, and finally assessing its severity based on EASL guidelines.\n            </strategic_thinking_statement>\n\n            The patient's presentation strongly suggests Drug-Induced Liver Injury (DILI). The EASL guidelines classify DILI intointrinsic (predictable, dose-related) and idiosyncratic (unpredictable, not dose-related). Trimethoprim-sulfamethoxazole is listed as a drug associated with idiosyncratic DILI [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1,https://storage.googleapis.com/easl-pdf/DILI.pdf]. Idiosyncratic DILI typically has a variable latency to onset of days to weeks, which aligns with the patient developing symptoms six days after starting the medication [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILIClassification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The guidelines emphasize that DILI diagnosis largely relies on the exclusion of alternative causes of liver damage [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Therefore, while DILI is highly suspected, a comprehensive workup to rule out other etiologies (e.g., viral hepatitis, ischemic hepatitis) would be necessary.\n\n            To classify the pattern of liver injury, the EASL guidelines recommend calculating the R-ratio (ALT/ULN / ALP/ULN). Liver injury is designated 'hepatocellular' if ALT alone is elevated \u22655-fold above ULN or R \u22655. It is 'cholestatic' if ALP alone is elevated \u22652-fold above ULN or R\u22642. A 'mixed' pattern is indicated when R >2 to <5 [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The patient's ALT(1650 U/L) and AST (2100 U/L) are markedly elevated, as is total bilirubin (12.5 mg/dL) and alkaline phosphatase (350 U/L). Assuming typical ULN values (e.g., ALT ULN ~40 U/L, ALP ULN ~120 U/L), the ALT is >40 times ULN and ALP is ~3 times ULN. This suggests a predominantly hepatocellular pattern, but the R-ratio needs precise calculation with actual ULN values.\n\n            The severity of DILI is assessed based on the presenceof symptoms such as jaundice, encephalopathy, and coagulopathy. The patient presents with jaundice, drowsiness, disorientation, and asterixis, which are clear signs of hepatic encephalopathy. The guidelines state that elevated aminotransferases in conjunction with jaundice reflect a higher risk of a severe outcome, a concept known as Hy\u2019slaw [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Patients with hepatocellular damage and jaundice have a mortality/liver transplant rate exceeding 10% [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The presence of encephalopathy further indicates severe DILI. The patient's history of rheumatoidarthritis treated with methotrexate is also relevant, as methotrexate is listed as an immunomodulatory drug associated with idiosyncratic DILI, and drug-associated fatty liver disease [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf], [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic Liver Disease, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. While methotrexate is a chronic medication, its potential contribution to underlying liver vulnerability should be considered.Lisinopril is also listed as a drug associated with idiosyncratic DILI [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf], though the acute onset after trimethoprim-sulfamethoxazole makes the latter the primary suspect.\n</DIVERGENT>\n\n<LOCAL_DIVERGENT>\n            <strategic_thinking_statement>\n                The clinical intent is to diagnose the cause, pattern, and severity of acute liver injury in this patient, considering local guidelines. The key patient anchors are theacute onset of symptoms, recent trimethoprim-sulfamethoxazole use, and severe liver enzyme derangements with encephalopathy. The local guidelines provided do not directly address the diagnosis, classification, or severity assessment of Drug-Induced Liver Injury (DILI). Therefore, this section will note the absence of specific local guidance forthis particular clinical scenario.\n            </strategic_thinking_statement>\n\n            The provided local guidelines, \"Tacrolimus for the treatment of autoimmune liver disease,\" \"Alcohol and the Liver,\" and \"Liver ablation - A guide for patients,\" do not contain information relevant to the daily diagnostic approach for acute drug-induced liver injury, itsclassification, or severity assessment. These documents focus on specific treatments (tacrolimus, liver ablation) or conditions (alcohol-related liver disease, ascites management) that are not directly applicable to the immediate diagnostic question regarding DILI. Therefore, there is no specific local guideline evidence to apply to the diagnostic steps for DILI in this patient's case.\n</LOCAL_DIVERGENT>\n\n<CONVERGENT>\n            The clinical intent is to diagnose the cause, pattern, and severity of acute liver injury in Sarah Miller.\n\n            Given the patient's acute presentation following the initiation of trimethoprim-sulfamethoxazole, Drug-Induced Liver Injury (DILI) is the primary hypothesis. Trimethoprim-sulfamethoxazole is explicitly listed as a drug associated with idiosyncratic DILI, and the onset within six days is consistent with the variable latency of days to weeks for idiosyncratic DILI [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n            To classify the pattern of liver injury, we need to calculate the R-ratio. Assuming standard Upper Limit of Normal (ULN) values (e.g., ALT ULN ~40 U/L, ALP ULN ~120 U/L):\n            *   ALT multiple of ULN = 1650 / 40 = 41.25\n            *   ALP multiple of ULN = 350 / 120 =2.92\n            *   R-ratio = (ALT multiple of ULN) / (ALP multiple of ULN) = 41.25 / 2.92 \u2248 14.1\n\n            Given an R-ratio of approximately 14.1, which is \u22655, the pattern of liver injury is classified as **hepatocellular** [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The patient's ALT elevation (1650 U/L) is also significantly greater than 5 times ULN, further supporting a hepatocellular pattern [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n            Regarding severity, the patient presents with jaundice (total bilirubin 12.5 mg/dL) and signs of hepatic encephalopathy (drowsiness, disorientation, asterixis). The EASL guidelines state that \"elevated aminotransferases in conjunction with jaundice, however, are well-known to reflect a higher risk of a severeoutcome. This was pointed out by Hyman Zimmerman several decades ago and became the basis for Hy\u2019s law\" [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Furthermore, the presence of encephalopathy indicates a severe form of DILI. Patients with hepatocellular damage and jaundice have a mortality/liver transplant rate exceeding 10% [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n            The patient's history of methotrexate use for rheumatoid arthritis is also relevant, as methotrexate is an immunomodulatory drug associated with DILI and drug-associated fatty liver disease [cite: EASL Clinical Practice Guidelines: Drug-induced liverinjury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf], [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic Liver Disease, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. While trimethoprim-sulfamethoxazole is the acute trigger, methotrexate could contribute to underlying liver vulnerability. Lisinopril is also listed as a drug associated with idiosyncratic DILI [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf], but the temporal association points to the antibiotic.\n\n            **Comparative weighing:** The evidence strongly points to acute, severe, hepatocellular DILI likely caused by trimethoprim-sulfamethoxazole. The presence of jaundice and encephalopathyplaces this case under Hy's law, indicating a high risk of severe outcomes. The primary diagnostic challenge is to confirm DILI by excluding other causes of acute liver injury, as emphasized by the guidelines [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. This would involve testing for viral hepatitis (HAV, HBV, HCV, HEV, EBV, CMV), autoimmune hepatitis, and ischemic hepatitis, especially given the patient's age and comorbidities.\n\n            **Conditional pathways:***   If alternative causes are ruled out, DILI due to trimethoprim-sulfamethoxazole is confirmed.\n            *   If INR is elevated, it would further confirm impaired hepatocellular function and increase the severity grading.\n            *   If the patient's condition deteriorates, referral to a liver transplant unit shouldbe considered, especially if INR is elevated [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Aminotransferases, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n            **Synthesis & Recommendation:** Based on the EASL guidelines, SarahMiller's presentation is highly consistent with **acute, severe, hepatocellular Drug-Induced Liver Injury (DILI)**, most likely triggered by trimethoprim-sulfamethoxazole. The presence of jaundice and encephalopathy signifies a severe prognosis, falling under Hy's law. Immediate management should include discontinuation of the suspected offendingdrug (trimethoprim-sulfamethoxazole) and a thorough workup to exclude other causes of acute liver injury. Close monitoring of liver function, coagulation parameters (INR), and neurological status is crucial.\n</CONVERGENT>\n\n<LOCAL_CONVERGENT>\n            The clinical intent is to diagnosethe cause, pattern, and severity of acute liver injury in Sarah Miller using local guidelines.\n\n            The provided local guidelines (\"Tacrolimus for the treatment of autoimmune liver disease,\" \"Alcohol and the Liver,\" and \"Liver ablation - A guide for patients\") do not offer specific diagnostic criteria, classification, or severity assessment foracute drug-induced liver injury. These documents are focused on specific treatments or conditions unrelated to the acute DILI diagnostic process. Therefore, local guidelines do not provide direct guidance for the daily diagnostic steps in this patient's case.\n\n            **Synthesis & Recommendation:** As the local guidelines do not address the diagnosis, classification, or severity assessmentof acute DILI, the diagnostic approach must rely solely on the EASL guidelines.\n</LOCAL_CONVERGENT>\n\n<GAP_ANALYSIS>\n    - **Concordance**: There is no direct concordance as the local guidelines provided do not cover the diagnosis, classification, or severity assessment of Drug-InducedLiver Injury (DILI).\n    - **Divergence**: No divergence can be identified as the local guidelines do not address the specific clinical scenario of DILI diagnosis.\n    - **Gaps & Alternatives**: The local guidelines have a significant gap in providing guidance for the diagnosis, classification, and severity assessment ofacute DILI. The EASL guidelines comprehensively cover these aspects, including identifying implicated drugs, classifying injury patterns (hepatocellular, cholestatic, mixed), and assessing severity based on clinical and laboratory parameters (e.g., Hy's law).\n    - **Resolution Strategy**: In the absence of specific local guidelines forDILI diagnosis, the comprehensive recommendations from the EASL Clinical Practice Guidelines should be followed as the primary source of guidance for Sarah Miller's case.\n</GAP_ANALYSIS>\n\n<RISK_ANALYSIS>\n    For Sarah Miller, the primary risk is the progression of severe DILI to acute liver failure (ALF),given the presence of jaundice and encephalopathy, which places her under Hy's law and indicates a mortality/liver transplant rate exceeding 10% [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The elevated transaminases and bilirubin, coupled with confusion and asterixis, signify significant liver dysfunction and potential for rapid deterioration.\n\n    **Specific risks associated with the patient's profile:**\n    *   **Methotrexate use:** While not theacute trigger, chronic methotrexate use for rheumatoid arthritis can cause liver injury (e.g., drug-associated fatty liver disease) [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf], [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic Liver Disease, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. This pre-existing liver condition could potentially increase susceptibility to DILI from other agents or worsen its severity.\n    *   **Lisinopril:** Lisinopril is also listed as a drug associated with idiosyncratic DILI [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Althoughless likely to be the primary cause given the acute onset after trimethoprim-sulfamethoxazole, it represents a potential confounder or contributing factor.\n    *   **Mild chronic kidney disease:** This comorbidity might affect drug metabolism and excretion, potentially increasing exposure to hepatotoxic metabolites, although the guidelines do not explicitlydetail this for DILI.\n    *   **Age (63 years):** Older age can sometimes be associated with a cholestatic pattern of DILI, though this patient presents with a hepatocellular pattern [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1,https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n    **Technical feasibility issues:** The diagnostic process for DILI primarily involves laboratory tests and clinical assessment. The main \"technical\" challenge is the exclusion of alternative causes, which requires a systematic approach to viral, autoimmune, and ischemic etiologies. If the patient's INR becomes significantly elevated, it would indicate impaired hepatocellular function and necessitate urgent consideration for referral to a liver transplant unit [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Aminotransferases, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n</RISK_ANALYSIS>\n\n</THINKING>\n\n\n\n## Answer\n\n\n    <short_answer>\n    Based on EASL guidelines, Sarah Miller's presentation is consistent with acute, severe, hepatocellular Drug-Induced Liver Injury (DILI), most likely causedby trimethoprim-sulfamethoxazole. The presence of jaundice and hepatic encephalopathy indicates a severe prognosis, falling under Hy's law. The primary diagnostic step is to discontinue the suspected offending drug and perform a comprehensive workup to exclude other causes of acute liver injury. Local guidelines do not provide specific guidancefor DILI diagnosis, classification, or severity assessment.\n    </short_answer>\n\n    <detailed_answer>\n    Sarah Miller's clinical picture, characterized by severe fatigue, jaundice, epigastric pain, and confusion, developing six days after starting trimethoprim-sulfamethoxazole, stronglysuggests acute Drug-Induced Liver Injury (DILI). Trimethoprim-sulfamethoxazole is a known agent associated with idiosyncratic DILI, and the rapid onset aligns with the typical latency period for this type of reaction [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n    To classify the pattern of liver injury, the R-ratio (ALT/ULN / ALP/ULN) is calculated. With ALT at 1650 U/L and ALP at 350 U/L, assuming typical ULN values (e.g., ALT ULN ~40 U/L, ALP ULN ~120 U/L), the R-ratio is approximately 14.1 (41.25 / 2.92). An R-ratio \u22655, along with ALT>5 times ULN, classifies the injury as **hepatocellular** [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n\n    The severity of DILI is highdue to the presence of both jaundice (total bilirubin 12.5 mg/dL) and hepatic encephalopathy (drowsiness, disorientation, asterixis). The EASL guidelines highlight that elevated aminotransferases combined with jaundice indicate a higher risk of severe outcomes, a principle known as Hy's law.Patients meeting these criteria for hepatocellular damage and jaundice have a mortality/liver transplant rate exceeding 10% [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The presence of encephalopathy further confirms severe DILI.\n\n    The diagnostic process must also include the exclusion of alternative causes of liver damage, such as viral hepatitis (HAV, HBV, HCV, HEV, EBV, CMV), autoimmune hepatitis, and ischemic hepatitis, as this is a cornerstone of DILI diagnosis [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The patient's history of methotrexate use and lisinopril are noted as both can be associated with DILI, butthe acute temporal association points to trimethoprim-sulfamethoxazole as the primary suspect. Close monitoring of INR is also critical, as elevated INR suggests impaired hepatocellular function and may necessitate referral to a liver transplant unit [cite: EASL Clinical Practice Guidelines: Drug-induced liver injury-Aminotransferases, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].\n    </detailed_answer>\n\n    <GAP_SUMMARY>\n    The local guidelines provided do not contain any information regarding the diagnosis, classification, or severity assessment of Drug-Induced Liver Injury (DILI). Therefore, there is asignificant gap in local guidance for this specific clinical scenario. The EASL guidelines offer comprehensive recommendations for identifying implicated drugs, classifying injury patterns (hepatocellular, cholestatic, mixed), and assessing severity based on clinical and laboratory parameters, including the application of Hy's law. In this case, the EASL guidelines serve as the solesource of evidence-based recommendations for diagnosis.\n    </GAP_SUMMARY>\n    <LOCAL_GUIDELINE_LIST>\n    Here is the list of local guidelines that supports the reasoning.\n    {\n        \"local_guidelines\": [\n            {\n                \"name\": \"Tacrolimus forthe treatment of autoimmune liver disease\"\n            },\n            {\n                \"name\": \"Alcohol and the Liver\"\n            },\n            {\n                \"name\": \"Liver ablation - A guide for patients\"\n            }\n        ]\n    }\n    </LOCAL_GUIDELINE_LIST>\n    <guideline_references>\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"Idiosyncratic DILI isusually not dose-related, although a dose threshold of 50\u2013100 mg/day is usually required, occurs in only a small proportion of exposed individuals (unpredictable) and exhibits a variable latency to onset of days to weeks. Drugs known to produce intrinsic and idiosyncratic DILI are presented in Table 1.... Sulfonamides\"\n    }\n    ,\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"Hepatocellular pattern: If ALT alone is elevated \u22655-fold above ULN or R \u22655. ... When the ratio of the serum activity of ALT to ALP is between 2 and 5, liver injury is termed \u2018mixed\u2019.160 As the liver enzyme elevations evolve over a period oftime, the pattern of DILI is determined by the first set of laboratory tests available in relation to the clinical event.\"\n    }\n    ,\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"The diagnosis of DILI largely relies on the exclusion of alternative causes of liver damage. The pattern of injury can aid in the initial diagnostic approach to rule out the most common causes of hepatitis and cholestasis (Fig. 2).\"\n    }\n    ,\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"Elevated aminotransferases in conjunction with jaundice, however, are well-known to reflect a higher risk of a severe outcome. This was pointed out by Hyman Zimmerman several decades ago and became the basis for Hy\u2019s law (see Section Detecting DILI in clinical trials for a moredetailed description), whereby the mortality/- transplantation rate was approximately 10% in patients with drug-induced jaundice.\"\n    }\n    ,\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic Liver Disease\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"Components of metabolic syndrome should be considered risk factors for the occurrence and the degree of DAFLD in patients treated with tamoxifen and methotrexate.\"\n    }\n    ,\n    {\n    \"Source\": \"EASL Clinical Practice Guidelines: Drug-induced liver injury-Aminotransferases\",\n    \"Link\": \"https://storage.googleapis.com/easl-pdf/DILI.pdf\",\n    \"Supporting\": \"Elevated INR values, which suggest impending liver failure, should prompt referral to a liver transplant unit.\"\n    }\n    </guideline_references>\n",
                "timestamp": "2025-11-14T15:57:02.725Z",
                "metadata": {
                    "chatId": "4pqPIK5Zmixt73wiUQaV",
                    "messageId": "ai-5136d6ce-a4e9-46f5-89d0-05effeb5edc8",
                    "expertName": "General Liver Disease Expert",
                    "source": "easl-chat",
                    "hasReasoning": true,
                    "hasSafetyAnalysis": true,
                    "hasLocalGuidelineAnalysis": false,
                    "timestamp": "2025-11-14T15:57:02.529Z"
                },
                "response_type": "chat"
            }
        ],
        "createdAt": "2025-10-28T12:00:00.000Z",
        "updatedAt": "2025-11-14T15:57:02.725Z"
    },
    {
        "id": "easl-clear-chats-button",
        "type": "button",
        "x": 4300,
        "y": 7050,
        "width": 200,
        "height": 45,
        "buttonText": "Clear Chats",
        "buttonIcon": "",
        "buttonColor": "#ffffff",
        "buttonTextColor": "#000000",
        "buttonAction": "clearChats",
        "createdAt": "2025-11-14T12:00:00.000Z",
        "updatedAt": "2025-11-14T12:00:00.000Z"
    },
    {
        "id": "ehr-hub-nervecentre",
        "type": "ehrHub",
        "x": -700,
        "y": -5400,
        "width": 350,
        "height": 250,
        "data": {
            "label": "Nervecentre EPR",
            "count": 6,
            "description": "Primary EPR system for clinical encounters",
            "color": "#9C27b0"
        },
        "createdAt": "2025-11-06T12:00:00.000Z",
        "updatedAt": "2025-11-06T12:00:00.000Z"
    },
    {
        "id": "ehr-hub-medilogik",
        "type": "ehrHub",
        "x": 920,
        "y": -3350,
        "width": 350,
        "height": 250,
        "data": {
            "label": "Medilogik EMS",
            "count": 1,
            "description": "Endoscopy management system",
            "color": "#00BCd4"
        },
        "createdAt": "2025-11-06T12:00:00.000Z",
        "updatedAt": "2025-11-06T12:00:00.000Z"
    },
    {
        "id": "ehr-hub-viper",
        "type": "ehrHub",
        "x": 200,
        "y": -3350,
        "width": 350,
        "height": 250,
        "data": {
            "label": "VIPER Ultrasound",
            "count": 1,
            "description": "Point-of-care ultrasound",
            "color": "#FF5722"
        },
        "createdAt": "2025-11-06T12:00:00.000Z",
        "updatedAt": "2025-11-06T12:00:00.000Z"
    },
    {
        "id": "ehr-hub-ice",
        "type": "ehrHub",
        "x": -1380,
        "y": -3350,
        "width": 350,
        "height": 250,
        "data": {
            "label": "ICE Laboratory",
            "count": 5,
            "description": "Laboratory information system",
            "color": "#2196F3"
        },
        "createdAt": "2025-11-06T12:00:00.000Z",
        "updatedAt": "2025-11-06T12:00:00.000Z"
    },
    {
        "id": "ehr-hub-bighand",
        "type": "ehrHub",
        "x": 2200,
        "y": -5400,
        "width": 350,
        "height": 250,
        "data": {
            "label": "BigHand Dictation",
            "count": 3,
            "description": "Clinical dictation and transcription",
            "color": "#4caf50"
        },
        "createdAt": "2025-11-06T12:00:00.000Z",
        "updatedAt": "2025-11-06T12:00:00.000Z"
    },
    {
        "id": "subzone-nervecentre",
        "type": "zone",
        "x": -2350,
        "y": -4800,
        "width": 3700,
        "height": 1100,
        "data": {
            "label": "Nervecentre EPR Data",
            "color": "#3b82f6",
            "handlePosition": "top"
        },
        "style": {
            "background": "linear-gradient(135deg, rgba(59, 130, 246, 0.08) 0%, rgba(59, 130, 246, 0.12) 100%)",
            "border": "2px solid #3b82f6",
            "borderRadius": "12px",
            "pointerEvents": "none"
        },
        "draggable": false,
        "selectable": false,
        "zIndex": -2,
        "createdAt": "2025-11-06T14:00:00.000Z",
        "updatedAt": "2025-11-06T14:00:00.000Z"
    },
    {
        "id": "subzone-ice",
        "type": "zone",
        "x": -2400,
        "y": -2700,
        "width": 2400,
        "height": 900,
        "data": {
            "label": "ICE Laboratory Data",
            "color": "#3b82f6",
            "handlePosition": "top"
        },
        "style": {
            "background": "linear-gradient(135deg, rgba(59, 130, 246, 0.08) 0%, rgba(59, 130, 246, 0.12) 100%)",
            "border": "2px solid #3b82f6",
            "borderRadius": "12px",
            "pointerEvents": "none"
        },
        "draggable": false,
        "selectable": false,
        "zIndex": -2,
        "createdAt": "2025-11-06T14:00:00.000Z",
        "updatedAt": "2025-11-06T14:00:00.000Z"
    },
    {
        "id": "subzone-bighand",
        "type": "zone",
        "x": 1500,
        "y": -4800,
        "width": 1800,
        "height": 900,
        "data": {
            "label": "BigHand Dictation Data",
            "color": "#3b82f6",
            "handlePosition": "top"
        },
        "style": {
            "background": "linear-gradient(135deg, rgba(59, 130, 246, 0.08) 0%, rgba(59, 130, 246, 0.12) 100%)",
            "border": "2px solid #3b82f6",
            "borderRadius": "12px",
            "pointerEvents": "none"
        },
        "draggable": false,
        "selectable": false,
        "zIndex": -2,
        "createdAt": "2025-11-06T14:00:00.000Z",
        "updatedAt": "2025-11-06T14:00:00.000Z"
    },
    {
        "id": "subzone-medilogik",
        "type": "zone",
        "x": 800,
        "y": -2700,
        "width": 600,
        "height": 900,
        "data": {
            "label": "Medilogik EMS Data",
            "color": "#3b82f6",
            "handlePosition": "top"
        },
        "style": {
            "background": "linear-gradient(135deg, rgba(59, 130, 246, 0.08) 0%, rgba(59, 130, 246, 0.12) 100%)",
            "border": "2px solid #3b82f6",
            "borderRadius": "12px",
            "pointerEvents": "none"
        },
        "draggable": false,
        "selectable": false,
        "zIndex": -2,
        "createdAt": "2025-11-06T14:00:00.000Z",
        "updatedAt": "2025-11-06T14:00:00.000Z"
    },
    {
        "id": "subzone-viper",
        "type": "zone",
        "x": 100,
        "y": -2700,
        "width": 600,
        "height": 900,
        "data": {
            "label": "VIPER Ultrasound Data",
            "color": "#3b82f6",
            "handlePosition": "top"
        },
        "style": {
            "background": "linear-gradient(135deg, rgba(59, 130, 246, 0.08) 0%, rgba(59, 130, 246, 0.12) 100%)",
            "border": "2px solid #3b82f6",
            "borderRadius": "12px",
            "pointerEvents": "none"
        },
        "draggable": false,
        "selectable": false,
        "zIndex": -2,
        "createdAt": "2025-11-06T14:00:00.000Z",
        "updatedAt": "2025-11-06T14:00:00.000Z"
    },
    {
        "id": "dashboard-item-generate-diagnosis-button",
        "type": "button",
        "x": 420,
        "y": 7100,
        "width": 650,
        "height": 50,
        "buttonText": "Generate DILI Diagnosis",
        "buttonIcon": "",
        "buttonColor": "#1E88E5",
        "buttonAction": "generateDiagnosis",
        "draggable": false,
        "createdAt": "2025-11-10T16:00:00.000Z",
        "updatedAt": "2025-11-10T16:00:00.000Z"
    },
    {
        "id": "dashboard-item-generate-report-button",
        "type": "button",
        "x": 420,
        "y": 11550,
        "width": 650,
        "height": 50,
        "buttonText": "Generate Patient Report",
        "buttonIcon": "",
        "buttonColor": "#1E88E5",
        "buttonAction": "generateReport",
        "draggable": false,
        "createdAt": "2025-11-10T16:00:00.000Z",
        "updatedAt": "2025-11-10T16:00:00.000Z"
    },
    {
        "id": "dashboard-item-share-board-to-hepato",
        "type": "button",
        "x": 1425,
        "y": 10480,
        "width": 650,
        "height": 50,
        "buttonText": "Share the board to Hepatologist",
        "buttonIcon": "",
        "buttonColor": "#2196F3",
        "buttonAction": "shareToHepato",
        "showHandles": true,
        "handlePosition": "left",
        "draggable": false,
        "createdAt": "2025-11-10T16:00:00.000Z",
        "updatedAt": "2025-11-10T16:00:00.000Z"
    },
    {
        "id": "dashboard-item-hepato-referal-decline",
        "type": "button",
        "x": 1425,
        "y": 10850,
        "width": 650,
        "height": 50,
        "buttonText": "Decline Hepatologist Referral",
        "buttonIcon": "",
        "buttonColor": "#F44336",
        "buttonAction": "declineHepato",
        "showHandles": true,
        "handlePosition": "left",
        "draggable": false,
        "createdAt": "2025-11-10T16:00:00.000Z",
        "updatedAt": "2025-11-10T16:00:00.000Z"
    },
    {
        "id": "dashboard-item-push-to-ehr-new",
        "type": "button",
        "x": 425,
        "y": 14600,
        "width": 650,
        "height": 50,
        "buttonText": "Push to EHR System",
        "buttonIcon": "",
        "buttonColor": "#2196F3",
        "buttonAction": "pushToEHR",
        "showHandles": true,
        "draggable": false,
        "createdAt": "2025-11-10T16:00:00.000Z",
        "updatedAt": "2025-11-10T16:00:00.000Z"
    },
    {
        "id": "item-1763116561512-517r7c",
        "type": "dili-diagnostic",
        "x": -80,
        "y": 7210,
        "width": 1600,
        "height": 700,
        "content": "DILI Diagnostic Panel",
        "color": "#ffffff",
        "rotation": 0,
        "diliData": {
            "pattern": {
                "classification": "Hepatocellular",
                "R_ratio": 31.9,
                "keyLabs": [
                    {
                        "label": "ALT",
                        "value": "1650 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "AST",
                        "value": "2100 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "ALP",
                        "value": "350 U/L",
                        "note": "\u2191"
                    },
                    {
                        "label": "Total Bilirubin",
                        "value": "12.5 mg/dL",
                        "note": "\u2191\u2191 (jaundiced)"
                    },
                    {
                        "label": "INR",
                        "value": "1",
                        "note": "Normal (but PTT prolonged)"
                    }
                ],
                "clinicalFeatures": [
                    "Severe fatigue",
                    "Jaundice",
                    "Epigastric pain",
                    "Confusion",
                    "Nausea",
                    "Oral mucosal ulcerations"
                ]
            },
            "causality": {
                "primaryDrug": "Trimethoprim-Sulfamethoxazole",
                "contributingFactors": [
                    "Methotrexate (hepatotoxic; drug interaction)",
                    "Age (63)",
                    "Alcohol consumption (1-2 beers/day)"
                ],
                "mechanisticRationale": [
                    "TMP-SMX can potentiate methotrexate toxicity.",
                    "Both TMP-SMX and MTX are known hepatotoxins.",
                    "Patient developed symptoms within 6 days of TMP-SMX initiation.",
                    "Concomitant alcohol use can exacerbate liver injury."
                ]
            },
            "severity": {
                "features": [
                    "Hepatic Encephalopathy (Asterixis, disorientation, GCS 13)",
                    "Coagulopathy (INR elevated, PTT prolonged)",
                    "Marked jaundice",
                    "Very high transaminases (ALT/AST >20x ULN)",
                    "Acute Liver Failure"
                ],
                "prognosis": "Life-threatening, requiring urgent intervention and ICU admission."
            },
            "management": {
                "immediateActions": [
                    "Discontinue Trimethoprim-Sulfamethoxazole.",
                    "Discontinue Methotrexate.",
                    "Initiate N-acetylcysteine protocol.",
                    "Admit to ICU for close monitoring.",
                    "Provide supportive care including IV fluids."
                ],
                "consults": [
                    "Hepatology",
                    "Gastroenterology",
                    "Hematology"
                ],
                "monitoringPlan": [
                    "Frequent neurological status checks.",
                    "Continuous vital signs monitoring.",
                    "Serial LFTs (ALT, AST, ALP, Bilirubin).",
                    "Serial INR/PTT.",
                    "Monitor for signs of bleeding or worsening encephalopathy.",
                    "Monitor Methotrexate levels."
                ]
            }
        },
        "createdAt": "2025-11-14T10:36:01.531Z",
        "updatedAt": "2025-11-14T10:36:01.531Z"
    },
    {
        "id": "item-1763116581691-onu3id",
        "type": "dili-diagnostic",
        "x": -80,
        "y": 7210,
        "width": 1600,
        "height": 700,
        "content": "DILI Diagnostic Panel",
        "color": "#ffffff",
        "rotation": 0,
        "diliData": {
            "pattern": {
                "classification": "Hepatocellular",
                "R_ratio": 31.9,
                "keyLabs": [
                    {
                        "label": "ALT",
                        "value": "1650 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "AST",
                        "value": "2100 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "ALP",
                        "value": "350 U/L",
                        "note": "\u2191"
                    },
                    {
                        "label": "Total Bilirubin",
                        "value": "12.5 mg/dL",
                        "note": "\u2191\u2191 (jaundiced)"
                    },
                    {
                        "label": "INR",
                        "value": "1",
                        "note": "Normal (but PTT prolonged)"
                    }
                ],
                "clinicalFeatures": [
                    "Severe fatigue",
                    "Jaundice",
                    "Epigastric pain",
                    "Confusion",
                    "Nausea",
                    "Oral mucosal ulcerations"
                ]
            },
            "causality": {
                "primaryDrug": "Trimethoprim-Sulfamethoxazole",
                "contributingFactors": [
                    "Methotrexate (hepatotoxic; drug interaction)",
                    "Age (63)",
                    "Alcohol consumption (1-2 beers/day)"
                ],
                "mechanisticRationale": [
                    "TMP-SMX can potentiate methotrexate toxicity.",
                    "Both TMP-SMX and MTX are known hepatotoxins.",
                    "Patient developed symptoms within 6 days of TMP-SMX initiation.",
                    "Concomitant alcohol use can exacerbate liver injury."
                ]
            },
            "severity": {
                "features": [
                    "Hepatic Encephalopathy (Asterixis, disorientation, GCS 13)",
                    "Coagulopathy (INR elevated, PTT prolonged)",
                    "Marked jaundice",
                    "Very high transaminases (ALT/AST >20x ULN)",
                    "Acute Liver Failure"
                ],
                "prognosis": "Life-threatening, requiring urgent intervention and ICU admission."
            },
            "management": {
                "immediateActions": [
                    "Discontinue Trimethoprim-Sulfamethoxazole.",
                    "Discontinue Methotrexate.",
                    "Initiate N-acetylcysteine protocol.",
                    "Admit to ICU for close monitoring.",
                    "Provide supportive care including IV fluids."
                ],
                "consults": [
                    "Hepatology",
                    "Gastroenterology",
                    "Hematology"
                ],
                "monitoringPlan": [
                    "Frequent neurological status checks.",
                    "Continuous vital signs monitoring.",
                    "Serial LFTs (ALT, AST, ALP, Bilirubin).",
                    "Serial INR/PTT.",
                    "Monitor for signs of bleeding or worsening encephalopathy.",
                    "Monitor Methotrexate levels."
                ]
            }
        },
        "createdAt": "2025-11-14T10:36:21.697Z",
        "updatedAt": "2025-11-14T10:36:21.697Z"
    },
    {
        "id": "item-1763116597917-spv19x",
        "type": "dili-diagnostic",
        "x": -80,
        "y": 7210,
        "width": 1600,
        "height": 700,
        "content": "DILI Diagnostic Panel",
        "color": "#ffffff",
        "rotation": 0,
        "diliData": {
            "pattern": {
                "classification": "Hepatocellular",
                "R_ratio": 31.9,
                "keyLabs": [
                    {
                        "label": "ALT",
                        "value": "1650 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "AST",
                        "value": "2100 U/L",
                        "note": "\u2191\u2191\u2191 (likely >20x ULN)"
                    },
                    {
                        "label": "ALP",
                        "value": "350 U/L",
                        "note": "\u2191"
                    },
                    {
                        "label": "Total Bilirubin",
                        "value": "12.5 mg/dL",
                        "note": "\u2191\u2191 (jaundiced)"
                    },
                    {
                        "label": "INR",
                        "value": "1",
                        "note": "Normal (but PTT prolonged)"
                    }
                ],
                "clinicalFeatures": [
                    "Severe fatigue",
                    "Jaundice",
                    "Epigastric pain",
                    "Confusion",
                    "Nausea",
                    "Oral mucosal ulcerations"
                ]
            },
            "causality": {
                "primaryDrug": "Trimethoprim-Sulfamethoxazole",
                "contributingFactors": [
                    "Methotrexate (hepatotoxic; drug interaction)",
                    "Age (63)",
                    "Alcohol consumption (1-2 beers/day)"
                ],
                "mechanisticRationale": [
                    "TMP-SMX can potentiate methotrexate toxicity.",
                    "Both TMP-SMX and MTX are known hepatotoxins.",
                    "Patient developed symptoms within 6 days of TMP-SMX initiation.",
                    "Concomitant alcohol use can exacerbate liver injury."
                ]
            },
            "severity": {
                "features": [
                    "Hepatic Encephalopathy (Asterixis, disorientation, GCS 13)",
                    "Coagulopathy (INR elevated, PTT prolonged)",
                    "Marked jaundice",
                    "Very high transaminases (ALT/AST >20x ULN)",
                    "Acute Liver Failure"
                ],
                "prognosis": "Life-threatening, requiring urgent intervention and ICU admission."
            },
            "management": {
                "immediateActions": [
                    "Discontinue Trimethoprim-Sulfamethoxazole.",
                    "Discontinue Methotrexate.",
                    "Initiate N-acetylcysteine protocol.",
                    "Admit to ICU for close monitoring.",
                    "Provide supportive care including IV fluids."
                ],
                "consults": [
                    "Hepatology",
                    "Gastroenterology",
                    "Hematology"
                ],
                "monitoringPlan": [
                    "Frequent neurological status checks.",
                    "Continuous vital signs monitoring.",
                    "Serial LFTs (ALT, AST, ALP, Bilirubin).",
                    "Serial INR/PTT.",
                    "Monitor for signs of bleeding or worsening encephalopathy.",
                    "Monitor Methotrexate levels."
                ]
            }
        },
        "createdAt": "2025-11-14T10:36:37.920Z",
        "updatedAt": "2025-11-14T10:36:37.920Z"
    },
    {
        "id": "item-1763116616790-xb49wb",
        "type": "patient-report",
        "x": -80,
        "y": 11660,
        "width": 1600,
        "height": 700,
        "content": "Patient Report",
        "color": "#ffffff",
        "rotation": 0,
        "patientData": {
            "name": "Sarah Miller",
            "date_of_birth": "1962-03-15",
            "age": 63,
            "sex": "Female",
            "mrn": "MC-001001",
            "primaryDiagnosis": "Rheumatoid arthritis",
            "problem_list": [
                {
                    "name": "Rheumatoid arthritis",
                    "status": "active"
                },
                {
                    "name": "Essential hypertension",
                    "status": "active"
                },
                {
                    "name": "Mild chronic kidney disease",
                    "status": "active"
                }
            ],
            "allergies": [
                "Penicillin (rash)"
            ],
            "medication_history": [
                {
                    "name": "Methotrexate",
                    "dose": "20 mg"
                },
                {
                    "name": "Folic Acid",
                    "dose": "5 mg"
                },
                {
                    "name": "Lisinopril",
                    "dose": "10 mg"
                },
                {
                    "name": "Trimethoprim-Sulfamethoxazole",
                    "dose": "800/160 mg"
                }
            ],
            "acute_event_summary": "Patient presented with severe fatigue, jaundice, epigastric pain, and confusion, consistent with acute liver injury.",
            "diagnosis_acute_event": [
                "Drug-Induced Liver Injury (DILI)",
                "Hepatic Encephalopathy",
                "Acute Liver Failure",
                "Methotrexate Toxicity"
            ],
            "causality": "The acute liver injury is likely due to a combination of Trimethoprim-Sulfamethoxazole-induced DILI and severe Methotrexate toxicity, exacerbated by the drug interaction between TMP-SMX and Methotrexate, the patient's age, and alcohol consumption.",
            "management_recommendations": [
                "Discontinue Trimethoprim-Sulfamethoxazole.",
                "Discontinue Methotrexate.",
                "Initiate N-acetylcysteine protocol.",
                "Admit to ICU for close monitoring.",
                "Provide supportive care including IV fluids.",
                "Consult Hepatology, Gastroenterology, and Hematology.",
                "Monitor neurological status, vital signs, LFTs, INR/PTT, and Methotrexate levels."
            ]
        },
        "createdAt": "2025-11-14T10:36:56.792Z",
        "updatedAt": "2025-11-14T10:36:56.792Z"
    },
    {
        "id": "enhanced-todo-1763135689014-ioiqnrgp0",
        "type": "todo",
        "x": 5860,
        "y": -2240,
        "width": 450,
        "height": "auto",
        "color": "#ffffff",
        "description": "Upload the most recent radiology data to the border system for further analysis.",
        "todoData": {
            "title": "Upload Latest Radiology Data to Border",
            "description": "Upload the most recent radiology data to the border system for further analysis.",
            "todos": [
                {
                    "id": "task-prep-upload",
                    "text": "Prepare latest radiology data for upload",
                    "status": "finished",
                    "agent": "data_preparer",
                    "subTodos": [
                        {
                            "text": "Identify and retrieve latest radiology dataset",
                            "status": "finished"
                        },
                        {
                            "text": "Validate data integrity and format",
                            "status": "finished"
                        },
                        {
                            "text": "Anonymize sensitive patient information if necessary",
                            "status": "finished"
                        }
                    ]
                },
                {
                    "id": "task-border-upload",
                    "text": "Upload radiology data to the border system",
                    "status": "finished",
                    "agent": "data_uploader",
                    "subTodos": [
                        {
                            "text": "Establish connection to the border system API",
                            "status": "finished"
                        },
                        {
                            "text": "Construct upload request payload",
                            "status": "finished"
                        },
                        {
                            "text": "Execute data upload via API",
                            "status": "finished"
                        },
                        {
                            "text": "Verify successful data ingestion on border system",
                            "status": "finished"
                        }
                    ]
                }
            ]
        },
        "rotation": 0,
        "createdAt": "2025-11-14T15:54:49.020Z",
        "updatedAt": "2025-11-14T15:55:12.485Z"
    },
    {
        "id": "item-1763135715230-hx5f85",
        "type": "agent",
        "x": 1560,
        "y": -3740,
        "width": 520,
        "height": 540,
        "content": "---\n\n### Sarah Miller \u2013 Radiology Diagnostic Summary\n\n**Patient:** Sarah Miller (MRN: MC-001001)  \n**Date Range Reviewed:** 2015-01-01 to 2025-11-14  \n**Modalities:** Not specified in request, data not directly available.  \n**Status:** Final\n\n#### Radiology Reports Retrieved\n\nNo radiology reports were directly retrieved or provided in the patient data. The task \"Upload Latest Radiology Data to Border\" implies a need to access and potentially upload such data, but no specific reports are listed or described within the provided encounter information.\n\n#### Findings Summary\n\nAs no radiology reports were available, a summary of findings cannot be generated.\n\n#### Impression\n\nGiven the absence of radiology data, no impression can be formed based on imaging.\n\n#### Audit & Review\n\n*   Reviewed patient context, medication history, and adverse event analytics related to a recent acute liver injury.\n*   The \"Upload Latest Radiology Data to Border\" task was identified, but no specific radiology reports were found within the provided patient encounter data.\n*   Therefore, data preparation and upload steps could not be completed as no radiology data was identified for retrieval.\n*   The \"border system API\" and \"upload request payload\" are not detailed in the provided data.\n\n---",
        "color": "#ffffff",
        "rotation": 0,
        "agentData": {
            "title": "Upload latest radiology data to border",
            "markdown": "---\n\n### Sarah Miller \u2013 Radiology Diagnostic Summary\n\n**Patient:** Sarah Miller (MRN: MC-001001)  \n**Date Range Reviewed:** 2015-01-01 to 2025-11-14  \n**Modalities:** Not specified in request, data not directly available.  \n**Status:** Final\n\n#### Radiology Reports Retrieved\n\nNo radiology reports were directly retrieved or provided in the patient data. The task \"Upload Latest Radiology Data to Border\" implies a need to access and potentially upload such data, but no specific reports are listed or described within the provided encounter information.\n\n#### Findings Summary\n\nAs no radiology reports were available, a summary of findings cannot be generated.\n\n#### Impression\n\nGiven the absence of radiology data, no impression can be formed based on imaging.\n\n#### Audit & Review\n\n*   Reviewed patient context, medication history, and adverse event analytics related to a recent acute liver injury.\n*   The \"Upload Latest Radiology Data to Border\" task was identified, but no specific radiology reports were found within the provided patient encounter data.\n*   Therefore, data preparation and upload steps could not be completed as no radiology data was identified for retrieval.\n*   The \"border system API\" and \"upload request payload\" are not detailed in the provided data.\n\n---"
        },
        "createdAt": "2025-11-14T15:55:15.237Z",
        "updatedAt": "2025-11-14T15:55:15.237Z"
    },
    {
        "id": "enhanced-todo-1763135772237-t8oyspk1m",
        "type": "todo",
        "x": 6440,
        "y": -2240,
        "width": 450,
        "height": "auto",
        "color": "#ffffff",
        "description": "Handling query to EASL Guideline Agent in background",
        "todoData": {
            "title": "EASL Guideline Query Workflow",
            "description": "Handling query to EASL Guideline Agent in background",
            "todos": [
                {
                    "id": "task-101",
                    "text": "Creating question query and generating context",
                    "status": "finished",
                    "agent": "Data Analyst Agent",
                    "subTodos": [
                        {
                            "text": "Base question : Can you make a daily diagnostic based on EASL guidelines?",
                            "status": "finished"
                        },
                        {
                            "text": "Detailed Question is generated by ContextGen Agent : Sarah Miller, a 63-year-old female with a history of rheumatoid arthritis treated with methotrexate, essential hypertension managed with lisinopril, and mild chronic kidney disease, presented to the emergency department with severe fatigue, jaundice, epigastric pain, and confusion six days after starting trimethoprim-sulfamethoxazole for acute bacterial sinusitis. Examination revealed jaundice, drowsiness, disorientation, and asterixis. Lab results showed ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and alkaline phosphatase 350 U/L. Can you make a daily diagnostic based on EASL guidelines?\n",
                            "status": "finished"
                        }
                    ]
                },
                {
                    "id": "task-102",
                    "text": "Send query to EASL Guideline Agent",
                    "status": "finished",
                    "agent": "Data Analyst Agent",
                    "subTodos": [
                        {
                            "text": "Query is processing",
                            "status": "finished"
                        },
                        {
                            "text": "Result is created in canvas",
                            "status": "finished"
                        }
                    ]
                }
            ]
        },
        "rotation": 0,
        "createdAt": "2025-11-14T15:56:12.241Z",
        "updatedAt": "2025-11-14T15:56:29.291Z"
    },
    {
        "id": "enhanced-todo-1763135835190-as6j9ev1p",
        "type": "todo",
        "x": 7020,
        "y": -2240,
        "width": 450,
        "height": "auto",
        "color": "#ffffff",
        "description": "Generate a comprehensive report for Sarah Miller.",
        "todoData": {
            "title": "Patient Report Generation",
            "description": "Generate a comprehensive report for Sarah Miller.",
            "todos": [
                {
                    "id": "task-report-001",
                    "text": "Gather patient information for Sarah Miller",
                    "status": "finished",
                    "agent": "data_retriever",
                    "subTodos": [
                        {
                            "text": "Retrieve patient demographic details",
                            "status": "finished"
                        },
                        {
                            "text": "Fetch medical history records",
                            "status": "finished"
                        },
                        {
                            "text": "Collect recent test results",
                            "status": "finished"
                        },
                        {
                            "text": "Obtain medication list",
                            "status": "finished"
                        }
                    ]
                },
                {
                    "id": "task-report-002",
                    "text": "Analyze collected patient data",
                    "status": "finished",
                    "agent": "data_analyst",
                    "subTodos": [
                        {
                            "text": "Identify key findings and trends",
                            "status": "finished"
                        },
                        {
                            "text": "Note any abnormalities or significant events",
                            "status": "finished"
                        },
                        {
                            "text": "Synthesize information for report sections",
                            "status": "finished"
                        }
                    ]
                },
                {
                    "id": "task-report-003",
                    "text": "Compile and format the report",
                    "status": "finished",
                    "agent": "report_generator",
                    "subTodos": [
                        {
                            "text": "Structure the report document",
                            "status": "finished"
                        },
                        {
                            "text": "Incorporate analyzed data and findings",
                            "status": "finished"
                        },
                        {
                            "text": "Add patient identifiers and date",
                            "status": "finished"
                        },
                        {
                            "text": "Review and proofread the report",
                            "status": "finished"
                        }
                    ]
                }
            ]
        },
        "rotation": 0,
        "createdAt": "2025-11-14T15:57:15.195Z",
        "updatedAt": "2025-11-14T15:57:49.453Z"
    },
    {
        "id": "item-1763135872703-zrc20s",
        "type": "agent",
        "x": 2140,
        "y": -3740,
        "width": 520,
        "height": 800,
        "content": "---\n\n### Sarah Miller \u2013 Clinical Summary and Acute Event Report\n\n**Patient:** Sarah Miller\n**MRN:** MC-001001\n**Date of Birth:** 1962-03-15\n**Age:** 63\n**Sex:** Female\n\n**Problem List:**\n*   Rheumatoid arthritis (active)\n*   Essential hypertension (active)\n*   Mild chronic kidney disease (active)\n\n**Allergies:** Penicillin (rash)\n\n---\n\n#### Recent Acute Event Summary: Acute Liver Injury\n\n**Encounter Date:** 2025-06-21 (Emergency Department)\n\n**Presenting Complaint:** Severe fatigue, jaundice, epigastric pain, confusion.\n\n**History of Present Illness:**\nThe patient developed symptoms approximately 6 days after initiating Trimethoprim-Sulfamethoxazole (TMP-SMX) for acute bacterial sinusitis. Symptoms included severe fatigue, jaundice, epigastric pain, and confusion. Nausea and oral mucosal ulcerations were also noted in the preceding days.\n\n**Physical Examination Findings (Emergency Department):**\n*   **General:** Ill-appearing, jaundiced, drowsy. Disoriented to time and place.\n*   **Neurological:** Asterixis present. Glasgow Coma Scale (GCS) 13 (E4 V3 M6).\n*   **Abdomen:** Soft, mild epigastric tenderness. No hepatosplenomegaly or ascites.\n*   **Vitals:** BP 142/90, HR 75, RR 18, Temp 36.9\u00b0C.\n\n**Key Laboratory Findings (2025-06-21):**\n*   **Liver Function Tests:**\n    *   ALT (SGPT): 1650 U/L (Reference: 7-56) - Markedly elevated\n    *   AST (SGOT): 2100 U/L (Reference: 8-40) - Markedly elevated\n    *   Total Bilirubin: 12.5 mg/dL (Reference: 0.2-1.2) - Markedly elevated\n    *   Alkaline Phosphatase: 350 U/L (Reference: 40-150) - Elevated\n    *   INR: 1.0 (Reference: 0.8-1.2) - Normal; PTT prolonged (not specified value)\n*   **Renal Function:** Creatinine: 1.5 mg/dL (Reference: 0.7-1.3) - Elevated; eGFR: 58 mL/min/1.73m\u00b2 (Reference: >60) - Reduced\n*   **Complete Blood Count:** WBC: 5.0 x10^9/L, Hemoglobin: 14.5 g/dL, Platelets: 165 x10^9/L - Within normal limits for the most part, though close to lower limit for platelets.\n\n**Assessment and Diagnosis:**\n*   **Acute Liver Injury:** Likely Drug-Induced Liver Injury (DILI), severe.\n*   **Pattern of Injury:** Hepatocellular (R-ratio approx. 14.1 based on assumed ULN values).\n*   **Causality:** Probable link to Trimethoprim-Sulfamethoxazole, with Methotrexate as a significant contributing factor due to drug interaction and potential underlying hepatotoxicity.\n*   **Severity:** Severe, consistent with Hy's Law, indicated by marked elevations in transaminases and bilirubin, coupled with hepatic encephalopathy.\n*   **Differential Diagnosis:** Severe Methotrexate toxicity, acute viral hepatitis, other drug-induced liver injuries, sepsis.\n\n**Management Plan (Emergency Department & ICU Admission):**\n*   Discontinue Trimethoprim-Sulfamethoxazole.\n*   Discontinue Methotrexate.\n*   Initiate N-acetylcysteine protocol.\n*   Admit to Intensive Care Unit (ICU) for close monitoring.\n*   Provide supportive care, including IV fluids.\n*   Consultations: Hepatology, Gastroenterology, Hematology.\n*   Monitoring: Frequent neurological checks, continuous vital signs, serial liver function tests, INR/PTT, and Methotrexate levels.\n\n---\n\n#### Chronic Medical History Relevant to Current Event\n\n**Rheumatoid Arthritis:** Diagnosed in 2015, managed with Methotrexate (initially 10mg weekly, increased to 20mg weekly in 2018) and Folic Acid. Generally well-controlled prior to the acute event.\n\n**Essential Hypertension:** Diagnosed in 2018, managed with Lisinopril 10mg daily. Blood pressure was reported as controlled.\n\n**Mild Chronic Kidney Disease:** Diagnosed by 2021, stable eGFR around 58-65 mL/min/1.73m\u00b2.\n\n**Medication Use:**\n*   **Methotrexate:** 20 mg weekly (started 2018-09-05)\n*   **Folic Acid:** 5 mg weekly (started 2015-08-10)\n*   **Lisinopril:** 10 mg daily (started 2018-09-05)\n*   **Trimethoprim-Sulfamethoxazole:** 800/160 mg BID (started 2025-06-15, ended 2025-06-25 due to acute illness)\n\n---\n\n#### Audit & Review\n\n*   **Data Reviewed:** Patient demographic details, medical history records (including Rheumatoid Arthritis, Hypertension, CKD), recent test results (acute liver injury labs), and medication lists. Clinical notes from multiple encounters detailing the progression of RA, HTN, and the events leading to the acute liver injury. Adverse Event Analytics and DILI Diagnostic information were also reviewed.\n*   **Analysis:** Key findings and trends indicate a drug-induced liver injury, likely exacerbated by drug interactions. Abnormalities noted include severe elevations in liver enzymes, bilirubin, and signs of hepatic encephalopathy.\n*   **Report Compilation:** The report is structured to provide a clear summary of the patient's current acute condition, relevant chronic history, and diagnostic considerations based on available data.\n\n---",
        "color": "#ffffff",
        "rotation": 0,
        "agentData": {
            "title": "Patient report generation",
            "markdown": "---\n\n### Sarah Miller \u2013 Clinical Summary and Acute Event Report\n\n**Patient:** Sarah Miller\n**MRN:** MC-001001\n**Date of Birth:** 1962-03-15\n**Age:** 63\n**Sex:** Female\n\n**Problem List:**\n*   Rheumatoid arthritis (active)\n*   Essential hypertension (active)\n*   Mild chronic kidney disease (active)\n\n**Allergies:** Penicillin (rash)\n\n---\n\n#### Recent Acute Event Summary: Acute Liver Injury\n\n**Encounter Date:** 2025-06-21 (Emergency Department)\n\n**Presenting Complaint:** Severe fatigue, jaundice, epigastric pain, confusion.\n\n**History of Present Illness:**\nThe patient developed symptoms approximately 6 days after initiating Trimethoprim-Sulfamethoxazole (TMP-SMX) for acute bacterial sinusitis. Symptoms included severe fatigue, jaundice, epigastric pain, and confusion. Nausea and oral mucosal ulcerations were also noted in the preceding days.\n\n**Physical Examination Findings (Emergency Department):**\n*   **General:** Ill-appearing, jaundiced, drowsy. Disoriented to time and place.\n*   **Neurological:** Asterixis present. Glasgow Coma Scale (GCS) 13 (E4 V3 M6).\n*   **Abdomen:** Soft, mild epigastric tenderness. No hepatosplenomegaly or ascites.\n*   **Vitals:** BP 142/90, HR 75, RR 18, Temp 36.9\u00b0C.\n\n**Key Laboratory Findings (2025-06-21):**\n*   **Liver Function Tests:**\n    *   ALT (SGPT): 1650 U/L (Reference: 7-56) - Markedly elevated\n    *   AST (SGOT): 2100 U/L (Reference: 8-40) - Markedly elevated\n    *   Total Bilirubin: 12.5 mg/dL (Reference: 0.2-1.2) - Markedly elevated\n    *   Alkaline Phosphatase: 350 U/L (Reference: 40-150) - Elevated\n    *   INR: 1.0 (Reference: 0.8-1.2) - Normal; PTT prolonged (not specified value)\n*   **Renal Function:** Creatinine: 1.5 mg/dL (Reference: 0.7-1.3) - Elevated; eGFR: 58 mL/min/1.73m\u00b2 (Reference: >60) - Reduced\n*   **Complete Blood Count:** WBC: 5.0 x10^9/L, Hemoglobin: 14.5 g/dL, Platelets: 165 x10^9/L - Within normal limits for the most part, though close to lower limit for platelets.\n\n**Assessment and Diagnosis:**\n*   **Acute Liver Injury:** Likely Drug-Induced Liver Injury (DILI), severe.\n*   **Pattern of Injury:** Hepatocellular (R-ratio approx. 14.1 based on assumed ULN values).\n*   **Causality:** Probable link to Trimethoprim-Sulfamethoxazole, with Methotrexate as a significant contributing factor due to drug interaction and potential underlying hepatotoxicity.\n*   **Severity:** Severe, consistent with Hy's Law, indicated by marked elevations in transaminases and bilirubin, coupled with hepatic encephalopathy.\n*   **Differential Diagnosis:** Severe Methotrexate toxicity, acute viral hepatitis, other drug-induced liver injuries, sepsis.\n\n**Management Plan (Emergency Department & ICU Admission):**\n*   Discontinue Trimethoprim-Sulfamethoxazole.\n*   Discontinue Methotrexate.\n*   Initiate N-acetylcysteine protocol.\n*   Admit to Intensive Care Unit (ICU) for close monitoring.\n*   Provide supportive care, including IV fluids.\n*   Consultations: Hepatology, Gastroenterology, Hematology.\n*   Monitoring: Frequent neurological checks, continuous vital signs, serial liver function tests, INR/PTT, and Methotrexate levels.\n\n---\n\n#### Chronic Medical History Relevant to Current Event\n\n**Rheumatoid Arthritis:** Diagnosed in 2015, managed with Methotrexate (initially 10mg weekly, increased to 20mg weekly in 2018) and Folic Acid. Generally well-controlled prior to the acute event.\n\n**Essential Hypertension:** Diagnosed in 2018, managed with Lisinopril 10mg daily. Blood pressure was reported as controlled.\n\n**Mild Chronic Kidney Disease:** Diagnosed by 2021, stable eGFR around 58-65 mL/min/1.73m\u00b2.\n\n**Medication Use:**\n*   **Methotrexate:** 20 mg weekly (started 2018-09-05)\n*   **Folic Acid:** 5 mg weekly (started 2015-08-10)\n*   **Lisinopril:** 10 mg daily (started 2018-09-05)\n*   **Trimethoprim-Sulfamethoxazole:** 800/160 mg BID (started 2025-06-15, ended 2025-06-25 due to acute illness)\n\n---\n\n#### Audit & Review\n\n*   **Data Reviewed:** Patient demographic details, medical history records (including Rheumatoid Arthritis, Hypertension, CKD), recent test results (acute liver injury labs), and medication lists. Clinical notes from multiple encounters detailing the progression of RA, HTN, and the events leading to the acute liver injury. Adverse Event Analytics and DILI Diagnostic information were also reviewed.\n*   **Analysis:** Key findings and trends indicate a drug-induced liver injury, likely exacerbated by drug interactions. Abnormalities noted include severe elevations in liver enzymes, bilirubin, and signs of hepatic encephalopathy.\n*   **Report Compilation:** The report is structured to provide a clear summary of the patient's current acute condition, relevant chronic history, and diagnostic considerations based on available data.\n\n---"
        },
        "createdAt": "2025-11-14T15:57:52.708Z",
        "updatedAt": "2025-11-14T15:57:52.708Z"
    }
]